EP4267114A1 - Nanoparticules de zéine destinées à être utilisées dans des pathologies avec hyperglycémie - Google Patents
Nanoparticules de zéine destinées à être utilisées dans des pathologies avec hyperglycémieInfo
- Publication number
- EP4267114A1 EP4267114A1 EP21840943.1A EP21840943A EP4267114A1 EP 4267114 A1 EP4267114 A1 EP 4267114A1 EP 21840943 A EP21840943 A EP 21840943A EP 4267114 A1 EP4267114 A1 EP 4267114A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- nanoparticle
- nanoparticles
- zein
- glucose levels
- fat accumulation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000002105 nanoparticle Substances 0.000 title claims abstract description 432
- 229920002494 Zein Polymers 0.000 title claims abstract description 238
- 239000005019 zein Substances 0.000 title claims abstract description 229
- 229940093612 zein Drugs 0.000 title claims abstract description 229
- 230000003345 hyperglycaemic effect Effects 0.000 title description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims abstract description 125
- 239000008103 glucose Substances 0.000 claims abstract description 125
- 238000011282 treatment Methods 0.000 claims abstract description 114
- 239000000203 mixture Substances 0.000 claims abstract description 100
- 238000009825 accumulation Methods 0.000 claims abstract description 71
- 150000001413 amino acids Chemical class 0.000 claims abstract description 70
- 230000002265 prevention Effects 0.000 claims abstract description 66
- 206010012601 diabetes mellitus Diseases 0.000 claims abstract description 52
- 239000011159 matrix material Substances 0.000 claims abstract description 35
- 229920001223 polyethylene glycol Polymers 0.000 claims description 126
- 208000008589 Obesity Diseases 0.000 claims description 58
- 235000020824 obesity Nutrition 0.000 claims description 58
- 239000002202 Polyethylene glycol Substances 0.000 claims description 57
- 238000000034 method Methods 0.000 claims description 49
- 235000013305 food Nutrition 0.000 claims description 47
- 208000001145 Metabolic Syndrome Diseases 0.000 claims description 41
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims description 41
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 37
- 239000003814 drug Substances 0.000 claims description 31
- 239000004480 active ingredient Substances 0.000 claims description 20
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 19
- 239000004472 Lysine Substances 0.000 claims description 19
- 239000003472 antidiabetic agent Substances 0.000 claims description 17
- 229940127003 anti-diabetic drug Drugs 0.000 claims description 14
- 238000004519 manufacturing process Methods 0.000 claims description 14
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims description 8
- 229960004580 glibenclamide Drugs 0.000 claims description 8
- ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 claims description 8
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 8
- 239000004475 Arginine Substances 0.000 claims description 7
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 7
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 7
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 7
- 230000001225 therapeutic effect Effects 0.000 abstract description 16
- 108010055615 Zein Proteins 0.000 description 186
- 241001465754 Metazoa Species 0.000 description 93
- 235000001014 amino acid Nutrition 0.000 description 59
- 235000019197 fats Nutrition 0.000 description 55
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 51
- 230000035508 accumulation Effects 0.000 description 46
- 239000000047 product Substances 0.000 description 38
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 36
- 241000700159 Rattus Species 0.000 description 33
- 230000000694 effects Effects 0.000 description 31
- -1 glycopyramide Chemical compound 0.000 description 31
- 108090000623 proteins and genes Proteins 0.000 description 31
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 30
- 235000005911 diet Nutrition 0.000 description 27
- 235000018102 proteins Nutrition 0.000 description 27
- 102000004169 proteins and genes Human genes 0.000 description 27
- 210000004369 blood Anatomy 0.000 description 26
- 239000008280 blood Substances 0.000 description 26
- 238000009472 formulation Methods 0.000 description 25
- 210000003097 mucus Anatomy 0.000 description 25
- 230000009467 reduction Effects 0.000 description 25
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 25
- 230000037213 diet Effects 0.000 description 24
- 201000010099 disease Diseases 0.000 description 24
- 239000000725 suspension Substances 0.000 description 24
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 23
- 241000699670 Mus sp. Species 0.000 description 22
- 230000032683 aging Effects 0.000 description 20
- 230000007423 decrease Effects 0.000 description 20
- 238000002474 experimental method Methods 0.000 description 19
- 229920000642 polymer Polymers 0.000 description 19
- 239000000243 solution Substances 0.000 description 19
- 102000004877 Insulin Human genes 0.000 description 18
- 108090001061 Insulin Proteins 0.000 description 18
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 18
- 229940079593 drug Drugs 0.000 description 18
- 229940125396 insulin Drugs 0.000 description 18
- 150000003626 triacylglycerols Chemical class 0.000 description 17
- 230000002829 reductive effect Effects 0.000 description 16
- 241000244206 Nematoda Species 0.000 description 15
- 238000009792 diffusion process Methods 0.000 description 15
- 230000012010 growth Effects 0.000 description 15
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 14
- 238000011156 evaluation Methods 0.000 description 14
- 238000001727 in vivo Methods 0.000 description 13
- 239000002417 nutraceutical Substances 0.000 description 13
- 235000021436 nutraceutical agent Nutrition 0.000 description 13
- 230000009469 supplementation Effects 0.000 description 13
- 241000283984 Rodentia Species 0.000 description 12
- 230000037396 body weight Effects 0.000 description 12
- 150000002632 lipids Chemical class 0.000 description 12
- 201000009104 prediabetes syndrome Diseases 0.000 description 12
- 239000007787 solid Substances 0.000 description 12
- 230000014509 gene expression Effects 0.000 description 11
- 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 description 10
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 description 10
- 102400000322 Glucagon-like peptide 1 Human genes 0.000 description 10
- 239000002552 dosage form Substances 0.000 description 10
- 239000002245 particle Substances 0.000 description 10
- 239000003981 vehicle Substances 0.000 description 10
- 102000000018 Chemokine CCL2 Human genes 0.000 description 9
- QCZAWDGAVJMPTA-RNFRBKRXSA-N ClC1=CC=CC(=N1)C1=NC(=NC(=N1)N[C@@H](C(F)(F)F)C)N[C@@H](C(F)(F)F)C Chemical compound ClC1=CC=CC(=N1)C1=NC(=NC(=N1)N[C@@H](C(F)(F)F)C)N[C@@H](C(F)(F)F)C QCZAWDGAVJMPTA-RNFRBKRXSA-N 0.000 description 9
- 206010018429 Glucose tolerance impaired Diseases 0.000 description 9
- 206010022489 Insulin Resistance Diseases 0.000 description 9
- 206010033307 Overweight Diseases 0.000 description 9
- 238000004458 analytical method Methods 0.000 description 9
- 235000012000 cholesterol Nutrition 0.000 description 9
- 230000000968 intestinal effect Effects 0.000 description 9
- 208000004611 Abdominal Obesity Diseases 0.000 description 8
- 206010065941 Central obesity Diseases 0.000 description 8
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 8
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 8
- 239000011248 coating agent Substances 0.000 description 8
- 238000000576 coating method Methods 0.000 description 8
- 235000020940 control diet Nutrition 0.000 description 8
- 230000003834 intracellular effect Effects 0.000 description 8
- 210000004185 liver Anatomy 0.000 description 8
- 239000008194 pharmaceutical composition Substances 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 230000008569 process Effects 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 101710155857 C-C motif chemokine 2 Proteins 0.000 description 7
- 108010010234 HDL Lipoproteins Proteins 0.000 description 7
- 102000015779 HDL Lipoproteins Human genes 0.000 description 7
- 206010020772 Hypertension Diseases 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 238000012423 maintenance Methods 0.000 description 7
- 230000004048 modification Effects 0.000 description 7
- 238000012986 modification Methods 0.000 description 7
- 238000011002 quantification Methods 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 6
- 208000002705 Glucose Intolerance Diseases 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 208000001280 Prediabetic State Diseases 0.000 description 6
- 241000700157 Rattus norvegicus Species 0.000 description 6
- 208000006011 Stroke Diseases 0.000 description 6
- 229930006000 Sucrose Natural products 0.000 description 6
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 6
- 240000008042 Zea mays Species 0.000 description 6
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 6
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 6
- 230000005856 abnormality Effects 0.000 description 6
- 235000005822 corn Nutrition 0.000 description 6
- 208000035475 disorder Diseases 0.000 description 6
- 238000007446 glucose tolerance test Methods 0.000 description 6
- 230000036541 health Effects 0.000 description 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 6
- 238000002483 medication Methods 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- 239000008213 purified water Substances 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 239000005720 sucrose Substances 0.000 description 6
- 241000282412 Homo Species 0.000 description 5
- 241000282414 Homo sapiens Species 0.000 description 5
- 206010056997 Impaired fasting glucose Diseases 0.000 description 5
- 241000124008 Mammalia Species 0.000 description 5
- 210000000577 adipose tissue Anatomy 0.000 description 5
- 230000003712 anti-aging effect Effects 0.000 description 5
- 239000012736 aqueous medium Substances 0.000 description 5
- 230000036765 blood level Effects 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 5
- 239000006185 dispersion Substances 0.000 description 5
- 238000006073 displacement reaction Methods 0.000 description 5
- 238000009826 distribution Methods 0.000 description 5
- ODKNJVUHOIMIIZ-RRKCRQDMSA-N floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 210000001596 intra-abdominal fat Anatomy 0.000 description 5
- 239000007928 intraperitoneal injection Substances 0.000 description 5
- 239000003550 marker Substances 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 description 5
- 229960001243 orlistat Drugs 0.000 description 5
- 229940124531 pharmaceutical excipient Drugs 0.000 description 5
- 239000002953 phosphate buffered saline Substances 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 230000004083 survival effect Effects 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 4
- 241000252983 Caecum Species 0.000 description 4
- 101100447050 Caenorhabditis elegans daf-16 gene Proteins 0.000 description 4
- 101100149536 Caenorhabditis elegans skn-1 gene Proteins 0.000 description 4
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 101100083855 Rattus norvegicus Pou2f3 gene Proteins 0.000 description 4
- YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 description 4
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 210000004534 cecum Anatomy 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 229920001577 copolymer Polymers 0.000 description 4
- 239000002577 cryoprotective agent Substances 0.000 description 4
- 230000034994 death Effects 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 230000007850 degeneration Effects 0.000 description 4
- 238000002296 dynamic light scattering Methods 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 201000010063 epididymitis Diseases 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- UPBDXRPQPOWRKR-UHFFFAOYSA-N furan-2,5-dione;methoxyethene Chemical compound COC=C.O=C1OC(=O)C=C1 UPBDXRPQPOWRKR-UHFFFAOYSA-N 0.000 description 4
- 150000002334 glycols Chemical class 0.000 description 4
- 230000002440 hepatic effect Effects 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- VOFUROIFQGPCGE-UHFFFAOYSA-N nile red Chemical compound C1=CC=C2C3=NC4=CC=C(N(CC)CC)C=C4OC3=CC(=O)C2=C1 VOFUROIFQGPCGE-UHFFFAOYSA-N 0.000 description 4
- 235000016709 nutrition Nutrition 0.000 description 4
- 238000003305 oral gavage Methods 0.000 description 4
- 230000036542 oxidative stress Effects 0.000 description 4
- HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 description 4
- 229940093429 polyethylene glycol 6000 Drugs 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 4
- 238000007619 statistical method Methods 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 229920000936 Agarose Polymers 0.000 description 3
- 208000024172 Cardiovascular disease Diseases 0.000 description 3
- 238000008157 ELISA kit Methods 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 229940123464 Thiazolidinedione Drugs 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 239000012190 activator Substances 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 230000000923 atherogenic effect Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000036772 blood pressure Effects 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 208000029078 coronary artery disease Diseases 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 230000003205 diastolic effect Effects 0.000 description 3
- 230000000378 dietary effect Effects 0.000 description 3
- 235000015872 dietary supplement Nutrition 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 230000002641 glycemic effect Effects 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 238000007912 intraperitoneal administration Methods 0.000 description 3
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 3
- FPYJFEHAWHCUMM-UHFFFAOYSA-N maleic anhydride Chemical compound O=C1OC(=O)C=C1 FPYJFEHAWHCUMM-UHFFFAOYSA-N 0.000 description 3
- 238000007726 management method Methods 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 230000007102 metabolic function Effects 0.000 description 3
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 3
- 229960003105 metformin Drugs 0.000 description 3
- XJRBAMWJDBPFIM-UHFFFAOYSA-N methyl vinyl ether Chemical compound COC=C XJRBAMWJDBPFIM-UHFFFAOYSA-N 0.000 description 3
- 230000035764 nutrition Effects 0.000 description 3
- 238000007410 oral glucose tolerance test Methods 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 238000006116 polymerization reaction Methods 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 230000006950 reactive oxygen species formation Effects 0.000 description 3
- 235000021487 ready-to-eat food Nutrition 0.000 description 3
- 238000001694 spray drying Methods 0.000 description 3
- 229910001220 stainless steel Inorganic materials 0.000 description 3
- 239000010935 stainless steel Substances 0.000 description 3
- 235000000891 standard diet Nutrition 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- 150000001467 thiazolidinediones Chemical class 0.000 description 3
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 3
- 230000004580 weight loss Effects 0.000 description 3
- XUFXOAAUWZOOIT-SXARVLRPSA-N (2R,3R,4R,5S,6R)-5-[[(2R,3R,4R,5S,6R)-5-[[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-1-cyclohex-2-enyl]amino]-2-oxanyl]oxy]-3,4-dihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-SXARVLRPSA-N 0.000 description 2
- BOVGTQGAOIONJV-BETUJISGSA-N 1-[(3ar,6as)-3,3a,4,5,6,6a-hexahydro-1h-cyclopenta[c]pyrrol-2-yl]-3-(4-methylphenyl)sulfonylurea Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)NN1C[C@H]2CCC[C@H]2C1 BOVGTQGAOIONJV-BETUJISGSA-N 0.000 description 2
- LLJFMFZYVVLQKT-UHFFFAOYSA-N 1-cyclohexyl-3-[4-[2-(7-methoxy-4,4-dimethyl-1,3-dioxo-2-isoquinolinyl)ethyl]phenyl]sulfonylurea Chemical compound C=1C(OC)=CC=C(C(C2=O)(C)C)C=1C(=O)N2CCC(C=C1)=CC=C1S(=O)(=O)NC(=O)NC1CCCCC1 LLJFMFZYVVLQKT-UHFFFAOYSA-N 0.000 description 2
- SWLAMJPTOQZTAE-UHFFFAOYSA-N 4-[2-[(5-chloro-2-methoxybenzoyl)amino]ethyl]benzoic acid Chemical class COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(C(O)=O)C=C1 SWLAMJPTOQZTAE-UHFFFAOYSA-N 0.000 description 2
- 239000005541 ACE inhibitor Substances 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- 108010039627 Aprotinin Proteins 0.000 description 2
- RKWGIWYCVPQPMF-UHFFFAOYSA-N Chloropropamide Chemical compound CCCNC(=O)NS(=O)(=O)C1=CC=C(Cl)C=C1 RKWGIWYCVPQPMF-UHFFFAOYSA-N 0.000 description 2
- FAEKWTJYAYMJKF-QHCPKHFHSA-N GlucoNorm Chemical compound C1=C(C(O)=O)C(OCC)=CC(CC(=O)N[C@@H](CC(C)C)C=2C(=CC=CC=2)N2CCCCC2)=C1 FAEKWTJYAYMJKF-QHCPKHFHSA-N 0.000 description 2
- 108010023302 HDL Cholesterol Proteins 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- YSDQQAXHVYUZIW-QCIJIYAXSA-N Liraglutide Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCNC(=O)CC[C@H](NC(=O)CCCCCCCCCCCCCCC)C(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=C(O)C=C1 YSDQQAXHVYUZIW-QCIJIYAXSA-N 0.000 description 2
- 108010019598 Liraglutide Proteins 0.000 description 2
- IBAQFPQHRJAVAV-ULAWRXDQSA-N Miglitol Chemical compound OCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO IBAQFPQHRJAVAV-ULAWRXDQSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 229920002538 Polyethylene Glycol 20000 Polymers 0.000 description 2
- 229920002584 Polyethylene Glycol 6000 Polymers 0.000 description 2
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 2
- 238000011529 RT qPCR Methods 0.000 description 2
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 229940100389 Sulfonylurea Drugs 0.000 description 2
- JLRGJRBPOGGCBT-UHFFFAOYSA-N Tolbutamide Chemical compound CCCCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1 JLRGJRBPOGGCBT-UHFFFAOYSA-N 0.000 description 2
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 description 2
- 102000040945 Transcription factor Human genes 0.000 description 2
- 108091023040 Transcription factor Proteins 0.000 description 2
- 229920004890 Triton X-100 Polymers 0.000 description 2
- 239000013504 Triton X-100 Substances 0.000 description 2
- FZNCGRZWXLXZSZ-CIQUZCHMSA-N Voglibose Chemical compound OCC(CO)N[C@H]1C[C@](O)(CO)[C@@H](O)[C@H](O)[C@H]1O FZNCGRZWXLXZSZ-CIQUZCHMSA-N 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 229960002632 acarbose Drugs 0.000 description 2
- XUFXOAAUWZOOIT-UHFFFAOYSA-N acarviostatin I01 Natural products OC1C(O)C(NC2C(C(O)C(O)C(CO)=C2)O)C(C)OC1OC(C(C1O)O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O XUFXOAAUWZOOIT-UHFFFAOYSA-N 0.000 description 2
- 229960001466 acetohexamide Drugs 0.000 description 2
- VGZSUPCWNCWDAN-UHFFFAOYSA-N acetohexamide Chemical compound C1=CC(C(=O)C)=CC=C1S(=O)(=O)NC(=O)NC1CCCCC1 VGZSUPCWNCWDAN-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 210000000593 adipose tissue white Anatomy 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 238000013019 agitation Methods 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 150000001370 alpha-amino acid derivatives Chemical class 0.000 description 2
- 235000008206 alpha-amino acids Nutrition 0.000 description 2
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 2
- 230000002921 anti-spasmodic effect Effects 0.000 description 2
- 229940065524 anticholinergics inhalants for obstructive airway diseases Drugs 0.000 description 2
- 239000001961 anticonvulsive agent Substances 0.000 description 2
- 229940124575 antispasmodic agent Drugs 0.000 description 2
- 229960004405 aprotinin Drugs 0.000 description 2
- 238000010009 beating Methods 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000000975 bioactive effect Effects 0.000 description 2
- 238000012742 biochemical analysis Methods 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 239000000090 biomarker Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 229960004111 buformin Drugs 0.000 description 2
- XSEUMFJMFFMCIU-UHFFFAOYSA-N buformin Chemical compound CCCC\N=C(/N)N=C(N)N XSEUMFJMFFMCIU-UHFFFAOYSA-N 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 238000005251 capillar electrophoresis Methods 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003638 chemical reducing agent Substances 0.000 description 2
- 229960001761 chlorpropamide Drugs 0.000 description 2
- 239000000812 cholinergic antagonist Substances 0.000 description 2
- 230000001713 cholinergic effect Effects 0.000 description 2
- RTIXKCRFFJGDFG-UHFFFAOYSA-N chrysin Chemical compound C=1C(O)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=CC=C1 RTIXKCRFFJGDFG-UHFFFAOYSA-N 0.000 description 2
- 229940124301 concurrent medication Drugs 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 description 2
- ZQSIJRDFPHDXIC-UHFFFAOYSA-N daidzein Chemical compound C1=CC(O)=CC=C1C1=COC2=CC(O)=CC=C2C1=O ZQSIJRDFPHDXIC-UHFFFAOYSA-N 0.000 description 2
- 235000013365 dairy product Nutrition 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000004807 desolvation Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 229940090124 dipeptidyl peptidase 4 (dpp-4) inhibitors for blood glucose lowering Drugs 0.000 description 2
- 230000006806 disease prevention Effects 0.000 description 2
- 239000002934 diuretic Substances 0.000 description 2
- 229940030606 diuretics Drugs 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 210000001198 duodenum Anatomy 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 235000013601 eggs Nutrition 0.000 description 2
- 210000000981 epithelium Anatomy 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 230000035611 feeding Effects 0.000 description 2
- XHEFDIBZLJXQHF-UHFFFAOYSA-N fisetin Chemical compound C=1C(O)=CC=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 XHEFDIBZLJXQHF-UHFFFAOYSA-N 0.000 description 2
- 238000002073 fluorescence micrograph Methods 0.000 description 2
- 235000013373 food additive Nutrition 0.000 description 2
- 238000005755 formation reaction Methods 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 229960000346 gliclazide Drugs 0.000 description 2
- 229960004346 glimepiride Drugs 0.000 description 2
- WIGIZIANZCJQQY-RUCARUNLSA-N glimepiride Chemical compound O=C1C(CC)=C(C)CN1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)N[C@@H]2CC[C@@H](C)CC2)C=C1 WIGIZIANZCJQQY-RUCARUNLSA-N 0.000 description 2
- 229960001381 glipizide Drugs 0.000 description 2
- ZJJXGWJIGJFDTL-UHFFFAOYSA-N glipizide Chemical compound C1=NC(C)=CN=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZJJXGWJIGJFDTL-UHFFFAOYSA-N 0.000 description 2
- 229960003468 gliquidone Drugs 0.000 description 2
- 229940093181 glucose injection Drugs 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000007407 health benefit Effects 0.000 description 2
- VUYDGVRIQRPHFX-UHFFFAOYSA-N hesperidin Natural products COc1cc(ccc1O)C2CC(=O)c3c(O)cc(OC4OC(COC5OC(O)C(O)C(O)C5O)C(O)C(O)C4O)cc3O2 VUYDGVRIQRPHFX-UHFFFAOYSA-N 0.000 description 2
- 235000009200 high fat diet Nutrition 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 239000011539 homogenization buffer Substances 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 230000005661 hydrophobic surface Effects 0.000 description 2
- WQYVRQLZKVEZGA-UHFFFAOYSA-N hypochlorite Chemical compound Cl[O-] WQYVRQLZKVEZGA-UHFFFAOYSA-N 0.000 description 2
- 230000002218 hypoglycaemic effect Effects 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 2
- 210000004347 intestinal mucosa Anatomy 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 238000001155 isoelectric focusing Methods 0.000 description 2
- 229960002725 isoflurane Drugs 0.000 description 2
- IYRMWMYZSQPJKC-UHFFFAOYSA-N kaempferol Chemical compound C1=CC(O)=CC=C1C1=C(O)C(=O)C2=C(O)C=C(O)C=C2O1 IYRMWMYZSQPJKC-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 229960002701 liraglutide Drugs 0.000 description 2
- 210000005228 liver tissue Anatomy 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 229920001427 mPEG Polymers 0.000 description 2
- 229920002521 macromolecule Polymers 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 210000001161 mammalian embryo Anatomy 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- 229950004994 meglitinide Drugs 0.000 description 2
- 230000004066 metabolic change Effects 0.000 description 2
- 208000030159 metabolic disease Diseases 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 229960001110 miglitol Drugs 0.000 description 2
- 230000000116 mitigating effect Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- UXOUKMQIEVGVLY-UHFFFAOYSA-N morin Natural products OC1=CC(O)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UXOUKMQIEVGVLY-UHFFFAOYSA-N 0.000 description 2
- 210000002200 mouth mucosa Anatomy 0.000 description 2
- 239000002077 nanosphere Substances 0.000 description 2
- 229960000698 nateglinide Drugs 0.000 description 2
- OELFLUMRDSZNSF-BRWVUGGUSA-N nateglinide Chemical compound C1C[C@@H](C(C)C)CC[C@@H]1C(=O)N[C@@H](C(O)=O)CC1=CC=CC=C1 OELFLUMRDSZNSF-BRWVUGGUSA-N 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 238000001543 one-way ANOVA Methods 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 2
- 229960003243 phenformin Drugs 0.000 description 2
- ICFJFFQQTFMIBG-UHFFFAOYSA-N phenformin Chemical compound NC(=N)NC(=N)NCCC1=CC=CC=C1 ICFJFFQQTFMIBG-UHFFFAOYSA-N 0.000 description 2
- 229960005095 pioglitazone Drugs 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 238000011552 rat model Methods 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 230000007115 recruitment Effects 0.000 description 2
- 229960002354 repaglinide Drugs 0.000 description 2
- 230000003252 repetitive effect Effects 0.000 description 2
- 230000004043 responsiveness Effects 0.000 description 2
- 229940016667 resveratrol Drugs 0.000 description 2
- 235000021283 resveratrol Nutrition 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 229960004586 rosiglitazone Drugs 0.000 description 2
- 238000004626 scanning electron microscopy Methods 0.000 description 2
- 238000001542 size-exclusion chromatography Methods 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- ATHGHQPFGPMSJY-UHFFFAOYSA-N spermidine Chemical compound NCCCCNCCCN ATHGHQPFGPMSJY-UHFFFAOYSA-N 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 230000007863 steatosis Effects 0.000 description 2
- 231100000240 steatosis hepatitis Toxicity 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 230000001360 synchronised effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000004797 therapeutic response Effects 0.000 description 2
- 229960002277 tolazamide Drugs 0.000 description 2
- OUDSBRTVNLOZBN-UHFFFAOYSA-N tolazamide Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)NN1CCCCCC1 OUDSBRTVNLOZBN-UHFFFAOYSA-N 0.000 description 2
- 229960005371 tolbutamide Drugs 0.000 description 2
- HJQILFPVRNHTIG-UHFFFAOYSA-N tolimidone Chemical compound CC1=CC=CC(OC2=CNC(=O)N=C2)=C1 HJQILFPVRNHTIG-UHFFFAOYSA-N 0.000 description 2
- 229950005012 tolimidone Drugs 0.000 description 2
- 229960001641 troglitazone Drugs 0.000 description 2
- GXPHKUHSUJUWKP-UHFFFAOYSA-N troglitazone Chemical compound C1CC=2C(C)=C(O)C(C)=C(C)C=2OC1(C)COC(C=C1)=CC=C1CC1SC(=O)NC1=O GXPHKUHSUJUWKP-UHFFFAOYSA-N 0.000 description 2
- GXPHKUHSUJUWKP-NTKDMRAZSA-N troglitazone Natural products C([C@@]1(OC=2C(C)=C(C(=C(C)C=2CC1)O)C)C)OC(C=C1)=CC=C1C[C@H]1SC(=O)NC1=O GXPHKUHSUJUWKP-NTKDMRAZSA-N 0.000 description 2
- 229910021642 ultra pure water Inorganic materials 0.000 description 2
- 239000012498 ultrapure water Substances 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 229960001729 voglibose Drugs 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- 239000001100 (2S)-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)chroman-4-one Substances 0.000 description 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical class OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- QKDRXGFQVGOQKS-CRSSMBPESA-N (2s,3r,4r,5s,6r)-2-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-6-methylsulfanyloxane-3,4,5-triol Chemical compound C1=CC(OCC)=CC=C1CC1=CC([C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](SC)O2)O)=CC=C1Cl QKDRXGFQVGOQKS-CRSSMBPESA-N 0.000 description 1
- FTVWIRXFELQLPI-ZDUSSCGKSA-N (S)-naringenin Chemical compound C1=CC(O)=CC=C1[C@H]1OC2=CC(O)=CC(O)=C2C(=O)C1 FTVWIRXFELQLPI-ZDUSSCGKSA-N 0.000 description 1
- PXEZTIWVRVSYOK-UHFFFAOYSA-N 2-(3,6-diacetyloxy-2,7-dichloro-9h-xanthen-9-yl)benzoic acid Chemical compound C1=2C=C(Cl)C(OC(=O)C)=CC=2OC2=CC(OC(C)=O)=C(Cl)C=C2C1C1=CC=CC=C1C(O)=O PXEZTIWVRVSYOK-UHFFFAOYSA-N 0.000 description 1
- 229940113178 5 Alpha reductase inhibitor Drugs 0.000 description 1
- GZSOSUNBTXMUFQ-NJGQXECBSA-N 5,7,3'-Trihydroxy-4'-methoxyflavone 7-O-rutinoside Natural products O(C[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](Oc2cc(O)c3C(=O)C=C(c4cc(O)c(OC)cc4)Oc3c2)O1)[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](C)O1 GZSOSUNBTXMUFQ-NJGQXECBSA-N 0.000 description 1
- NYCXYKOXLNBYID-UHFFFAOYSA-N 5,7-Dihydroxychromone Natural products O1C=CC(=O)C=2C1=CC(O)=CC=2O NYCXYKOXLNBYID-UHFFFAOYSA-N 0.000 description 1
- 239000002677 5-alpha reductase inhibitor Substances 0.000 description 1
- PQSUYGKTWSAVDQ-ZVIOFETBSA-N Aldosterone Chemical compound C([C@@]1([C@@H](C(=O)CO)CC[C@H]1[C@@H]1CC2)C=O)[C@H](O)[C@@H]1[C@]1(C)C2=CC(=O)CC1 PQSUYGKTWSAVDQ-ZVIOFETBSA-N 0.000 description 1
- PQSUYGKTWSAVDQ-UHFFFAOYSA-N Aldosterone Natural products C1CC2C3CCC(C(=O)CO)C3(C=O)CC(O)C2C2(C)C1=CC(=O)CC2 PQSUYGKTWSAVDQ-UHFFFAOYSA-N 0.000 description 1
- 241001156002 Anthonomus pomorum Species 0.000 description 1
- 238000009020 BCA Protein Assay Kit Methods 0.000 description 1
- FXNFHKRTJBSTCS-UHFFFAOYSA-N Baicalein Natural products C=1C(=O)C=2C(O)=C(O)C(O)=CC=2OC=1C1=CC=CC=C1 FXNFHKRTJBSTCS-UHFFFAOYSA-N 0.000 description 1
- 229940123208 Biguanide Drugs 0.000 description 1
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 230000005653 Brownian motion process Effects 0.000 description 1
- PWDLDBWXTVILPC-WGAVTJJLSA-N CC(C)(N)CC1=CC=CC=C1.C1O[C@@]2(COS(N)(=O)=O)OC(C)(C)O[C@H]2[C@@H]2OC(C)(C)O[C@@H]21 Chemical compound CC(C)(N)CC1=CC=CC=C1.C1O[C@@]2(COS(N)(=O)=O)OC(C)(C)O[C@H]2[C@@H]2OC(C)(C)O[C@@H]21 PWDLDBWXTVILPC-WGAVTJJLSA-N 0.000 description 1
- 241000244202 Caenorhabditis Species 0.000 description 1
- 241000244203 Caenorhabditis elegans Species 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 244000033714 Clidemia hirta Species 0.000 description 1
- 235000014277 Clidemia hirta Nutrition 0.000 description 1
- 101710112164 Cytochrome b6-f complex subunit 4 Proteins 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- JVHXJTBJCFBINQ-ADAARDCZSA-N Dapagliflozin Chemical compound C1=CC(OCC)=CC=C1CC1=CC([C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)=CC=C1Cl JVHXJTBJCFBINQ-ADAARDCZSA-N 0.000 description 1
- GCPYCNBGGPHOBD-UHFFFAOYSA-N Delphinidin Natural products OC1=Cc2c(O)cc(O)cc2OC1=C3C=C(O)C(=O)C(=C3)O GCPYCNBGGPHOBD-UHFFFAOYSA-N 0.000 description 1
- UBSCDKPKWHYZNX-UHFFFAOYSA-N Demethoxycapillarisin Natural products C1=CC(O)=CC=C1OC1=CC(=O)C2=C(O)C=C(O)C=C2O1 UBSCDKPKWHYZNX-UHFFFAOYSA-N 0.000 description 1
- QEVGZEDELICMKH-UHFFFAOYSA-N Diglycolic acid Chemical compound OC(=O)COCC(O)=O QEVGZEDELICMKH-UHFFFAOYSA-N 0.000 description 1
- 241000219762 Dioclea grandiflora Species 0.000 description 1
- 102100025012 Dipeptidyl peptidase 4 Human genes 0.000 description 1
- 238000011891 EIA kit Methods 0.000 description 1
- 101710198774 Envelope protein US9 Proteins 0.000 description 1
- 241000588722 Escherichia Species 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- HTQBXNHDCUEHJF-XWLPCZSASA-N Exenatide Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 HTQBXNHDCUEHJF-XWLPCZSASA-N 0.000 description 1
- 108010011459 Exenatide Proteins 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 108010068370 Glutens Proteins 0.000 description 1
- 241000208253 Gymnema sylvestre Species 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- QUQPHWDTPGMPEX-UHFFFAOYSA-N Hesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(COC4C(C(O)C(O)C(C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-UHFFFAOYSA-N 0.000 description 1
- 101000684208 Homo sapiens Prolyl endopeptidase FAP Proteins 0.000 description 1
- SHBUUTHKGIVMJT-UHFFFAOYSA-N Hydroxystearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OO SHBUUTHKGIVMJT-UHFFFAOYSA-N 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 229940122355 Insulin sensitizer Drugs 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 229920001202 Inulin Polymers 0.000 description 1
- 108010041872 Islet Amyloid Polypeptide Proteins 0.000 description 1
- 102000036770 Islet Amyloid Polypeptide Human genes 0.000 description 1
- GQODBWLKUWYOFX-UHFFFAOYSA-N Isorhamnetin Natural products C1=C(O)C(C)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 GQODBWLKUWYOFX-UHFFFAOYSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- YIICVSCAKJMMDJ-UHFFFAOYSA-N L-vasicine Natural products C1=CC=C2N=C3C(O)CCN3CC2=C1 YIICVSCAKJMMDJ-UHFFFAOYSA-N 0.000 description 1
- SDIVYZXRQHWCKF-UHFFFAOYSA-N L-vasicinone Natural products C1=CC=C2C(=O)N3CCC(O)C3=NC2=C1 SDIVYZXRQHWCKF-UHFFFAOYSA-N 0.000 description 1
- 238000008214 LDL Cholesterol Methods 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- LTXREWYXXSTFRX-QGZVFWFLSA-N Linagliptin Chemical compound N=1C=2N(C)C(=O)N(CC=3N=C4C=CC=CC4=C(C)N=3)C(=O)C=2N(CC#CC)C=1N1CCC[C@@H](N)C1 LTXREWYXXSTFRX-QGZVFWFLSA-N 0.000 description 1
- XVVOERDUTLJJHN-UHFFFAOYSA-N Lixisenatide Chemical compound C=1NC2=CC=CC=C2C=1CC(C(=O)NC(CC(C)C)C(=O)NC(CCCCN)C(=O)NC(CC(N)=O)C(=O)NCC(=O)NCC(=O)N1C(CCC1)C(=O)NC(CO)C(=O)NC(CO)C(=O)NCC(=O)NC(C)C(=O)N1C(CCC1)C(=O)N1C(CCC1)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)CC)NC(=O)C(NC(=O)C(CC(C)C)NC(=O)C(CCCNC(N)=N)NC(=O)C(NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(CCC(O)=O)NC(=O)C(CCC(O)=O)NC(=O)C(CCSC)NC(=O)C(CCC(N)=O)NC(=O)C(CCCCN)NC(=O)C(CO)NC(=O)C(CC(C)C)NC(=O)C(CC(O)=O)NC(=O)C(CO)NC(=O)C(NC(=O)C(CC=1C=CC=CC=1)NC(=O)C(NC(=O)CNC(=O)C(CCC(O)=O)NC(=O)CNC(=O)C(N)CC=1NC=NC=1)C(C)O)C(C)O)C(C)C)CC1=CC=CC=C1 XVVOERDUTLJJHN-UHFFFAOYSA-N 0.000 description 1
- WHSOLWOTCHFFBK-ZQGJOIPISA-N Luseogliflozin Chemical compound C1=CC(OCC)=CC=C1CC1=CC([C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)S2)O)=C(OC)C=C1C WHSOLWOTCHFFBK-ZQGJOIPISA-N 0.000 description 1
- 241000218922 Magnoliophyta Species 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 240000002129 Malva sylvestris Species 0.000 description 1
- 235000006770 Malva sylvestris Nutrition 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- MZSGWZGPESCJAN-MOBFUUNNSA-N Melitric acid A Natural products O([C@@H](C(=O)O)Cc1cc(O)c(O)cc1)C(=O)/C=C/c1cc(O)c(O/C(/C(=O)O)=C/c2cc(O)c(O)cc2)cc1 MZSGWZGPESCJAN-MOBFUUNNSA-N 0.000 description 1
- YXOLAZRVSSWPPT-UHFFFAOYSA-N Morin Chemical compound OC1=CC(O)=CC=C1C1=C(O)C(=O)C2=C(O)C=C(O)C=C2O1 YXOLAZRVSSWPPT-UHFFFAOYSA-N 0.000 description 1
- 208000016285 Movement disease Diseases 0.000 description 1
- 108700005084 Multigene Family Proteins 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 101100190845 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) pmp-1 gene Proteins 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 241001614207 Pamplona Species 0.000 description 1
- YIICVSCAKJMMDJ-SNVBAGLBSA-N Peganine Chemical compound C1=CC=C2N=C3[C@H](O)CCN3CC2=C1 YIICVSCAKJMMDJ-SNVBAGLBSA-N 0.000 description 1
- YIICVSCAKJMMDJ-JTQLQIEISA-N Peganine Natural products C1=CC=C2N=C3[C@@H](O)CCN3CC2=C1 YIICVSCAKJMMDJ-JTQLQIEISA-N 0.000 description 1
- 101000621749 Penicillium citrinum Peroxiredoxin Pen c 3 Proteins 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- NKSOSPOXQKNIKJ-CLFAGFIQSA-N Polyoxyethylene dioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCCOC(=O)CCCCCCC\C=C/CCCCCCCC NKSOSPOXQKNIKJ-CLFAGFIQSA-N 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 108091081062 Repeated sequence (DNA) Proteins 0.000 description 1
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 1
- DLSWIYLPEUIQAV-UHFFFAOYSA-N Semaglutide Chemical compound CCC(C)C(NC(=O)C(Cc1ccccc1)NC(=O)C(CCC(O)=O)NC(=O)C(CCCCNC(=O)COCCOCCNC(=O)COCCOCCNC(=O)CCC(NC(=O)CCCCCCCCCCCCCCCCC(O)=O)C(O)=O)NC(=O)C(C)NC(=O)C(C)NC(=O)C(CCC(N)=O)NC(=O)CNC(=O)C(CCC(O)=O)NC(=O)C(CC(C)C)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CO)NC(=O)C(CO)NC(=O)C(NC(=O)C(CC(O)=O)NC(=O)C(CO)NC(=O)C(NC(=O)C(Cc1ccccc1)NC(=O)C(NC(=O)CNC(=O)C(CCC(O)=O)NC(=O)C(C)(C)NC(=O)C(N)Cc1cnc[nH]1)C(C)O)C(C)O)C(C)C)C(=O)NC(C)C(=O)NC(Cc1c[nH]c2ccccc12)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CCCNC(N)=N)C(=O)NCC(O)=O DLSWIYLPEUIQAV-UHFFFAOYSA-N 0.000 description 1
- QLXKHBNJTPICNF-QMCAAQAGSA-N Sergliflozin etabonate Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](COC(=O)OCC)O[C@H]1OC1=CC=CC=C1CC1=CC=C(OC)C=C1 QLXKHBNJTPICNF-QMCAAQAGSA-N 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 229940123518 Sodium/glucose cotransporter 2 inhibitor Drugs 0.000 description 1
- 241000592344 Spermatophyta Species 0.000 description 1
- 101150084279 TM gene Proteins 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- ZXOCGDDVNPDRIW-NHFZGCSJSA-N Tofogliflozin Chemical compound O.C1=CC(CC)=CC=C1CC1=CC=C(CO[C@@]23[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)C2=C1 ZXOCGDDVNPDRIW-NHFZGCSJSA-N 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- SDIVYZXRQHWCKF-VIFPVBQESA-N Vasicinone Chemical compound C1=CC=C2C(=O)N3CC[C@H](O)C3=NC2=C1 SDIVYZXRQHWCKF-VIFPVBQESA-N 0.000 description 1
- SDIVYZXRQHWCKF-SECBINFHSA-N Vasicinone Natural products C1=CC=C2C(=O)N3CC[C@@H](O)C3=NC2=C1 SDIVYZXRQHWCKF-SECBINFHSA-N 0.000 description 1
- HIMJIPRMECETLJ-UHFFFAOYSA-N Wogonin Natural products COc1cc(O)c(O)c2C(=O)C=C(Oc12)c3ccccc3 HIMJIPRMECETLJ-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 229920006322 acrylamide copolymer Polymers 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 229960002478 aldosterone Drugs 0.000 description 1
- 150000005215 alkyl ethers Chemical class 0.000 description 1
- 229960001667 alogliptin Drugs 0.000 description 1
- ZSBOMTDTBDDKMP-OAHLLOKOSA-N alogliptin Chemical compound C=1C=CC=C(C#N)C=1CN1C(=O)N(C)C(=O)C=C1N1CCC[C@@H](N)C1 ZSBOMTDTBDDKMP-OAHLLOKOSA-N 0.000 description 1
- 229920005603 alternating copolymer Polymers 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 229940124326 anaesthetic agent Drugs 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 239000002333 angiotensin II receptor antagonist Substances 0.000 description 1
- 229940125364 angiotensin receptor blocker Drugs 0.000 description 1
- 150000008064 anhydrides Chemical group 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 229940069428 antacid Drugs 0.000 description 1
- 239000003159 antacid agent Substances 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000003288 anthiarrhythmic effect Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003257 anti-anginal effect Effects 0.000 description 1
- 230000001142 anti-diarrhea Effects 0.000 description 1
- 230000001090 anti-dopaminergic effect Effects 0.000 description 1
- 230000003474 anti-emetic effect Effects 0.000 description 1
- 230000003556 anti-epileptic effect Effects 0.000 description 1
- 230000000603 anti-haemophilic effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 229940124345 antianginal agent Drugs 0.000 description 1
- 239000003416 antiarrhythmic agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 229940125681 anticonvulsant agent Drugs 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 229940125708 antidiabetic agent Drugs 0.000 description 1
- 229940125714 antidiarrheal agent Drugs 0.000 description 1
- 239000003793 antidiarrheal agent Substances 0.000 description 1
- 229940125683 antiemetic agent Drugs 0.000 description 1
- 239000002111 antiemetic agent Substances 0.000 description 1
- 229960003965 antiepileptics Drugs 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 229940030225 antihemorrhagics Drugs 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000003430 antimalarial agent Substances 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 229940127218 antiplatelet drug Drugs 0.000 description 1
- 239000000164 antipsychotic agent Substances 0.000 description 1
- 229940005529 antipsychotics Drugs 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 229940125716 antipyretic agent Drugs 0.000 description 1
- 229940064004 antiseptic throat preparations Drugs 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 230000000949 anxiolytic effect Effects 0.000 description 1
- 229940005530 anxiolytics Drugs 0.000 description 1
- XADJWCRESPGUTB-UHFFFAOYSA-N apigenin Natural products C1=CC(O)=CC=C1C1=CC(=O)C2=CC(O)=C(O)C=C2O1 XADJWCRESPGUTB-UHFFFAOYSA-N 0.000 description 1
- 235000008714 apigenin Nutrition 0.000 description 1
- KZNIFHPLKGYRTM-UHFFFAOYSA-N apigenin Chemical compound C1=CC(O)=CC=C1C1=CC(=O)C2=C(O)C=C(O)C=C2O1 KZNIFHPLKGYRTM-UHFFFAOYSA-N 0.000 description 1
- 229940117893 apigenin Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- QUQPHWDTPGMPEX-UTWYECKDSA-N aurantiamarin Natural products COc1ccc(cc1O)[C@H]1CC(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2O1 QUQPHWDTPGMPEX-UTWYECKDSA-N 0.000 description 1
- 229940015301 baicalein Drugs 0.000 description 1
- UDFLTIRFTXWNJO-UHFFFAOYSA-N baicalein Chemical compound O1C2=CC(=O)C(O)=C(O)C2=C(O)C=C1C1=CC=CC=C1 UDFLTIRFTXWNJO-UHFFFAOYSA-N 0.000 description 1
- 229940125717 barbiturate Drugs 0.000 description 1
- 238000007681 bariatric surgery Methods 0.000 description 1
- 229940049706 benzodiazepine Drugs 0.000 description 1
- 150000001557 benzodiazepines Chemical class 0.000 description 1
- 150000004283 biguanides Chemical class 0.000 description 1
- 229920000080 bile acid sequestrant Polymers 0.000 description 1
- 229940096699 bile acid sequestrants Drugs 0.000 description 1
- 230000003851 biochemical process Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 238000005537 brownian motion Methods 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 229960001058 bupropion Drugs 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 235000012970 cakes Nutrition 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- 235000020827 calorie restriction Nutrition 0.000 description 1
- 229960001713 canagliflozin Drugs 0.000 description 1
- VHOFTEAWFCUTOS-TUGBYPPCSA-N canagliflozin hydrate Chemical compound O.CC1=CC=C([C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C=C1CC(S1)=CC=C1C1=CC=C(F)C=C1.CC1=CC=C([C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C=C1CC(S1)=CC=C1C1=CC=C(F)C=C1 VHOFTEAWFCUTOS-TUGBYPPCSA-N 0.000 description 1
- 239000003557 cannabinoid Substances 0.000 description 1
- 229930003827 cannabinoid Natural products 0.000 description 1
- 229940065144 cannabinoids Drugs 0.000 description 1
- 230000007963 carbohydrate restriction Effects 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 229940097217 cardiac glycoside Drugs 0.000 description 1
- 239000002368 cardiac glycoside Substances 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 235000015838 chrysin Nutrition 0.000 description 1
- 229940043370 chrysin Drugs 0.000 description 1
- APSNPMVGBGZYAJ-GLOOOPAXSA-N clematine Natural products COc1cc(ccc1O)[C@@H]2CC(=O)c3c(O)cc(O[C@@H]4O[C@H](CO[C@H]5O[C@@H](C)[C@H](O)[C@@H](O)[C@H]5O)[C@@H](O)[C@H](O)[C@H]4O)cc3O2 APSNPMVGBGZYAJ-GLOOOPAXSA-N 0.000 description 1
- 238000012411 cloning technique Methods 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 235000015140 cultured milk Nutrition 0.000 description 1
- 235000012754 curcumin Nutrition 0.000 description 1
- 229940109262 curcumin Drugs 0.000 description 1
- 239000004148 curcumin Substances 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 229940124569 cytoprotecting agent Drugs 0.000 description 1
- 235000007240 daidzein Nutrition 0.000 description 1
- 229960003834 dapagliflozin Drugs 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- JKHRCGUTYDNCLE-UHFFFAOYSA-O delphinidin Chemical compound [O+]=1C2=CC(O)=CC(O)=C2C=C(O)C=1C1=CC(O)=C(O)C(O)=C1 JKHRCGUTYDNCLE-UHFFFAOYSA-O 0.000 description 1
- 235000007242 delphinidin Nutrition 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 235000011850 desserts Nutrition 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000021045 dietary change Nutrition 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 1
- 235000001916 dieting Nutrition 0.000 description 1
- 230000037228 dieting effect Effects 0.000 description 1
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- GZSOSUNBTXMUFQ-YFAPSIMESA-N diosmin Chemical compound C1=C(O)C(OC)=CC=C1C(OC1=C2)=CC(=O)C1=C(O)C=C2O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@@H]([C@H](O)[C@@H](O)[C@H](C)O2)O)O1 GZSOSUNBTXMUFQ-YFAPSIMESA-N 0.000 description 1
- 229960004352 diosmin Drugs 0.000 description 1
- IGBKNLGEMMEWKD-UHFFFAOYSA-N diosmin Natural products COc1ccc(cc1)C2=C(O)C(=O)c3c(O)cc(OC4OC(COC5OC(C)C(O)C(O)C5O)C(O)C(O)C4O)cc3O2 IGBKNLGEMMEWKD-UHFFFAOYSA-N 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- UWBXIFCTIZXXLS-UHFFFAOYSA-L disodium;2,3,4,5-tetrachloro-6-(2,4,5,7-tetraiodo-3-oxido-6-oxoxanthen-9-yl)benzoate Chemical compound [Na+].[Na+].[O-]C(=O)C1=C(Cl)C(Cl)=C(Cl)C(Cl)=C1C1=C2C=C(I)C(=O)C(I)=C2OC2=C(I)C([O-])=C(I)C=C21 UWBXIFCTIZXXLS-UHFFFAOYSA-L 0.000 description 1
- 239000003210 dopamine receptor blocking agent Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 229940127257 dual PPAR agonist Drugs 0.000 description 1
- 229960005175 dulaglutide Drugs 0.000 description 1
- 108010005794 dulaglutide Proteins 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000005672 electromagnetic field Effects 0.000 description 1
- 239000002895 emetic Substances 0.000 description 1
- 229960003345 empagliflozin Drugs 0.000 description 1
- OBWASQILIWPZMG-QZMOQZSNSA-N empagliflozin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=CC=C(Cl)C(CC=2C=CC(O[C@@H]3COCC3)=CC=2)=C1 OBWASQILIWPZMG-QZMOQZSNSA-N 0.000 description 1
- TUJPOVKMHCLXEL-UHFFFAOYSA-N eriodictyol Natural products C1C(=O)C2=CC(O)=CC(O)=C2OC1C1=CC=C(O)C(O)=C1 TUJPOVKMHCLXEL-UHFFFAOYSA-N 0.000 description 1
- SBHXYTNGIZCORC-ZDUSSCGKSA-N eriodictyol Chemical compound C1([C@@H]2CC(=O)C3=C(O)C=C(C=C3O2)O)=CC=C(O)C(O)=C1 SBHXYTNGIZCORC-ZDUSSCGKSA-N 0.000 description 1
- 235000011797 eriodictyol Nutrition 0.000 description 1
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 1
- SBHXYTNGIZCORC-UHFFFAOYSA-N eriodyctiol Natural products O1C2=CC(O)=CC(O)=C2C(=O)CC1C1=CC=C(O)C(O)=C1 SBHXYTNGIZCORC-UHFFFAOYSA-N 0.000 description 1
- 235000020774 essential nutrients Nutrition 0.000 description 1
- 125000001033 ether group Chemical group 0.000 description 1
- DNJIEGIFACGWOD-UHFFFAOYSA-N ethyl mercaptane Natural products CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 description 1
- 125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000002270 exclusion chromatography Methods 0.000 description 1
- 229960001519 exenatide Drugs 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 230000003480 fibrinolytic effect Effects 0.000 description 1
- 235000011990 fisetin Nutrition 0.000 description 1
- 239000000834 fixative Substances 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 230000002431 foraging effect Effects 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 235000021255 galacto-oligosaccharides Nutrition 0.000 description 1
- 150000003271 galactooligosaccharides Chemical class 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000003633 gene expression assay Methods 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- 235000021472 generally recognized as safe Nutrition 0.000 description 1
- 229940045109 genistein Drugs 0.000 description 1
- 235000006539 genistein Nutrition 0.000 description 1
- TZBJGXHYKVUXJN-UHFFFAOYSA-N genistein Natural products C1=CC(O)=CC=C1C1=COC2=CC(O)=CC(O)=C2C1=O TZBJGXHYKVUXJN-UHFFFAOYSA-N 0.000 description 1
- ZCOLJUOHXJRHDI-CMWLGVBASA-N genistein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 ZCOLJUOHXJRHDI-CMWLGVBASA-N 0.000 description 1
- 208000004104 gestational diabetes Diseases 0.000 description 1
- 102000034238 globular proteins Human genes 0.000 description 1
- 108091005896 globular proteins Proteins 0.000 description 1
- 230000014101 glucose homeostasis Effects 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 235000021312 gluten Nutrition 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000036252 glycation Effects 0.000 description 1
- 230000000025 haemostatic effect Effects 0.000 description 1
- 235000004280 healthy diet Nutrition 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- QUQPHWDTPGMPEX-QJBIFVCTSA-N hesperidin Chemical compound C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO[C@H]4[C@@H]([C@H](O)[C@@H](O)[C@H](C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-QJBIFVCTSA-N 0.000 description 1
- 229940025878 hesperidin Drugs 0.000 description 1
- 235000020256 human milk Nutrition 0.000 description 1
- 210000004251 human milk Anatomy 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
- 229940072106 hydroxystearate Drugs 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 239000003326 hypnotic agent Substances 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 229940126904 hypoglycaemic agent Drugs 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 238000010191 image analysis Methods 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000006362 insulin response pathway Effects 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 1
- 229940029339 inulin Drugs 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 125000003010 ionic group Chemical group 0.000 description 1
- 229950000991 ipragliflozin Drugs 0.000 description 1
- AHFWIQIYAXSLBA-RQXATKFSSA-N ipragliflozin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=CC=C(F)C(CC=2SC3=CC=CC=C3C=2)=C1 AHFWIQIYAXSLBA-RQXATKFSSA-N 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 235000008800 isorhamnetin Nutrition 0.000 description 1
- IZQSVPBOUDKVDZ-UHFFFAOYSA-N isorhamnetin Chemical compound C1=C(O)C(OC)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 IZQSVPBOUDKVDZ-UHFFFAOYSA-N 0.000 description 1
- 150000002540 isothiocyanates Chemical class 0.000 description 1
- YAORRSXETYGIGC-UHFFFAOYSA-N isovasicinone Natural products C1=CC=C2C(=O)N3C(O)CCC3=NC2=C1 YAORRSXETYGIGC-UHFFFAOYSA-N 0.000 description 1
- 235000008777 kaempferol Nutrition 0.000 description 1
- 235000015141 kefir Nutrition 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- JCQLYHFGKNRPGE-FCVZTGTOSA-N lactulose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 JCQLYHFGKNRPGE-FCVZTGTOSA-N 0.000 description 1
- 229960000511 lactulose Drugs 0.000 description 1
- PFCRQPBOOFTZGQ-UHFFFAOYSA-N lactulose keto form Natural products OCC(=O)C(O)C(C(O)CO)OC1OC(CO)C(O)C(O)C1O PFCRQPBOOFTZGQ-UHFFFAOYSA-N 0.000 description 1
- 239000008141 laxative Substances 0.000 description 1
- 229940125722 laxative agent Drugs 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 229960004502 levodopa Drugs 0.000 description 1
- 229960002397 linagliptin Drugs 0.000 description 1
- 230000006372 lipid accumulation Effects 0.000 description 1
- 108010022197 lipoprotein cholesterol Proteins 0.000 description 1
- 229960001093 lixisenatide Drugs 0.000 description 1
- 108010004367 lixisenatide Proteins 0.000 description 1
- 238000004599 local-density approximation Methods 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- XTTZERNUQAFMOF-QMMMGPOBSA-N lorcaserin Chemical compound C[C@H]1CNCCC2=CC=C(Cl)C=C12 XTTZERNUQAFMOF-QMMMGPOBSA-N 0.000 description 1
- 229960005060 lorcaserin Drugs 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 229950004397 luseogliflozin Drugs 0.000 description 1
- LRDGATPGVJTWLJ-UHFFFAOYSA-N luteolin Natural products OC1=CC(O)=CC(C=2OC3=CC(O)=CC(O)=C3C(=O)C=2)=C1 LRDGATPGVJTWLJ-UHFFFAOYSA-N 0.000 description 1
- 235000009498 luteolin Nutrition 0.000 description 1
- IQPNAANSBPBGFQ-UHFFFAOYSA-N luteolin Chemical compound C=1C(O)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(O)C(O)=C1 IQPNAANSBPBGFQ-UHFFFAOYSA-N 0.000 description 1
- 238000003760 magnetic stirring Methods 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 235000013310 margarine Nutrition 0.000 description 1
- HHRZAEJMHSGZNP-UHFFFAOYSA-N mebanazine Chemical compound NNC(C)C1=CC=CC=C1 HHRZAEJMHSGZNP-UHFFFAOYSA-N 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 235000007708 morin Nutrition 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- WGEYAGZBLYNDFV-UHFFFAOYSA-N naringenin Natural products C1(=O)C2=C(O)C=C(O)C=C2OC(C1)C1=CC=C(CC1)O WGEYAGZBLYNDFV-UHFFFAOYSA-N 0.000 description 1
- 235000007625 naringenin Nutrition 0.000 description 1
- 229940117954 naringenin Drugs 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- ARGKVCXINMKCAZ-UHFFFAOYSA-N neohesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(CO)O3)OC3C(C(O)C(O)C(C)O3)O)=CC(O)=C2C(=O)C1 ARGKVCXINMKCAZ-UHFFFAOYSA-N 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 238000010534 nucleophilic substitution reaction Methods 0.000 description 1
- 235000021048 nutrient requirements Nutrition 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 235000020660 omega-3 fatty acid Nutrition 0.000 description 1
- 229940012843 omega-3 fatty acid Drugs 0.000 description 1
- 239000006014 omega-3 oil Substances 0.000 description 1
- 229940005483 opioid analgesics Drugs 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 235000014594 pastries Nutrition 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- XVFMGWDSJLBXDZ-UHFFFAOYSA-O pelargonidin Chemical compound C1=CC(O)=CC=C1C(C(=C1)O)=[O+]C2=C1C(O)=CC(O)=C2 XVFMGWDSJLBXDZ-UHFFFAOYSA-O 0.000 description 1
- HKUHOPQRJKPJCJ-UHFFFAOYSA-N pelargonidin Natural products OC1=Cc2c(O)cc(O)cc2OC1c1ccc(O)cc1 HKUHOPQRJKPJCJ-UHFFFAOYSA-N 0.000 description 1
- 235000006251 pelargonidin Nutrition 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 238000013379 physicochemical characterization Methods 0.000 description 1
- 235000017807 phytochemicals Nutrition 0.000 description 1
- 229930000223 plant secondary metabolite Natural products 0.000 description 1
- 239000000106 platelet aggregation inhibitor Substances 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 230000003334 potential effect Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 229960003611 pramlintide Drugs 0.000 description 1
- 108010029667 pramlintide Proteins 0.000 description 1
- NRKVKVQDUCJPIZ-MKAGXXMWSA-N pramlintide acetate Chemical compound C([C@@H](C(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CS)NC(=O)[C@@H](N)CCCCN)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 NRKVKVQDUCJPIZ-MKAGXXMWSA-N 0.000 description 1
- 235000013406 prebiotics Nutrition 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000000529 probiotic effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 229940126409 proton pump inhibitor Drugs 0.000 description 1
- 239000000612 proton pump inhibitor Substances 0.000 description 1
- 230000001337 psychedelic effect Effects 0.000 description 1
- 239000003196 psychodysleptic agent Substances 0.000 description 1
- 238000005086 pumping Methods 0.000 description 1
- 235000005875 quercetin Nutrition 0.000 description 1
- 229960001285 quercetin Drugs 0.000 description 1
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 1
- 150000007660 quinolones Chemical class 0.000 description 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 229950011516 remogliflozin etabonate Drugs 0.000 description 1
- UAOCLDQAQNNEAX-ABMICEGHSA-N remogliflozin etabonate Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](COC(=O)OCC)O[C@H]1OC1=NN(C(C)C)C(C)=C1CC1=CC=C(OC(C)C)C=C1 UAOCLDQAQNNEAX-ABMICEGHSA-N 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 235000005493 rutin Nutrition 0.000 description 1
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 1
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 1
- 229960004555 rutoside Drugs 0.000 description 1
- 229960004937 saxagliptin Drugs 0.000 description 1
- QGJUIPDUBHWZPV-SGTAVMJGSA-N saxagliptin Chemical compound C1C(C2)CC(C3)CC2(O)CC13[C@H](N)C(=O)N1[C@H](C#N)C[C@@H]2C[C@@H]21 QGJUIPDUBHWZPV-SGTAVMJGSA-N 0.000 description 1
- 108010033693 saxagliptin Proteins 0.000 description 1
- 238000001878 scanning electron micrograph Methods 0.000 description 1
- 238000007790 scraping Methods 0.000 description 1
- 230000000580 secretagogue effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 229950011186 semaglutide Drugs 0.000 description 1
- 108010060325 semaglutide Proteins 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 229950000378 sergliflozin etabonate Drugs 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 229960002930 sirolimus Drugs 0.000 description 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
- 229960004034 sitagliptin Drugs 0.000 description 1
- MFFMDFFZMYYVKS-SECBINFHSA-N sitagliptin Chemical compound C([C@H](CC(=O)N1CC=2N(C(=NN=2)C(F)(F)F)CC1)N)C1=CC(F)=C(F)C=C1F MFFMDFFZMYYVKS-SECBINFHSA-N 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 229940083608 sodium hydroxide Drugs 0.000 description 1
- SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 229950005268 sotagliflozin Drugs 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 229940063673 spermidine Drugs 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 229930002534 steroid glycoside Natural products 0.000 description 1
- 150000008143 steroidal glycosides Chemical class 0.000 description 1
- 239000000021 stimulant Substances 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000012134 supernatant fraction Substances 0.000 description 1
- 238000005211 surface analysis Methods 0.000 description 1
- 229950006667 tofogliflozin Drugs 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 238000007738 vacuum evaporation Methods 0.000 description 1
- 239000005526 vasoconstrictor agent Substances 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 229960001254 vildagliptin Drugs 0.000 description 1
- SYOKIDBDQMKNDQ-XWTIBIIYSA-N vildagliptin Chemical compound C1C(O)(C2)CC(C3)CC1CC32NCC(=O)N1CCC[C@H]1C#N SYOKIDBDQMKNDQ-XWTIBIIYSA-N 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- XLTFNNCXVBYBSX-UHFFFAOYSA-N wogonin Chemical compound COC1=C(O)C=C(O)C(C(C=2)=O)=C1OC=2C1=CC=CC=C1 XLTFNNCXVBYBSX-UHFFFAOYSA-N 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5169—Proteins, e.g. albumin, gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Definitions
- the invention relates to the use of zein nanoparticles in the treatment and/or prevention of conditions characterized by increased glucose levels and/or fat accumulation, in particular to the medical use in the treatment and/or prevention of diabetes, obesity or metabolic syndrome, and to the non-therapeutic use in extending the lifespan of an organism.
- Increased glucose levels and/or fat accumulation are involved in a variety of therapeutic and non-therapeutic conditions, such as diabetes and lifespan.
- anti-ageing compounds such as spermidine, rapamycin, metformin, or resveratrol
- spermidine a compound that has demonstrated the capability of delaying the consequences of ageing
- rapamycin a compound that has demonstrated the capability of delaying the consequences of ageing
- metformin a compound that has demonstrated the capability of delaying the consequences of ageing
- resveratrol a compound that has demonstrated the capability of delaying the consequences of ageing
- those that are most well-known are the antioxidants, calorie restriction mimetics, inductors of autophagy, senolytics, immunomodulators, telomerase activators and epigenetic drugs [A. M. Vaiserman et al., Ageing Res. Rev., 2016, 31, 9-35],
- Calorie restriction also known as a dietary restriction (DR)
- DR dietary restriction
- Diabetes is a global epidemic which is expected to grow up to 642 million patients by 2030.
- Diabetes is a chronic, metabolic disease characterized by elevated levels of blood glucose, which leads over time to serious damage to the heart, blood vessels, eyes, kidneys and nerves.
- Type 1 diabetes results from the pancreas’ failure to produce enough insulin.
- type 2 diabetes usually in adults, which occurs when the body becomes resistant to insulin or there is not enough insulin produced. This type of diabetes is largely the result of excess body weight and physical inactivity.
- Gestational diabetes occurs when pregnant women without a previous history of diabetes develop high blood glucose levels.
- Blood glucose levels are used for the diagnosis of diabetes, according to the following criteria: fasting plasma glucose level > 7.0 mmol/L (126 mg/dL) or plasma glucose > 11.1 mmol/L (200 mg/dL) two hours after a 75 g oral glucose load as in a glucose tolerance test. People with fasting glucose levels from 6.1 to 6.9 mmol/L (110 to 125 mg/dL) are considered to have impaired fasting glucose. People with plasma glucose at or above 7.8 mmol/L (140 mg/dL), but not over 11.1 mmol/L (200 mg/dL), two hours after a 75 gram oral glucose load are considered to have impaired glucose tolerance. These are considered prediabetic states.
- Diabetes management concentrates on keeping blood sugar levels as close to normal, without causing low blood sugar. This can usually be accomplished with dietary changes, exercise, weight loss, and use of appropriate medications.
- Most medications used to treat diabetes act by lowering blood sugar levels through different mechanisms. These medications are known as hypoglycemic agents, antidiabetic agents, or antihyperglycemic agents.
- bisguanides, thiazolidinediones, and LYN kinease activators are insulin sensitizers, which address the problem of insulin resistance. Biguanides, such as metformin, phenformin and buformin, reduce hepatic glucose output and increase uptake of glucose by the periphery.
- Thiazolidinediones such as rosiglitazone, pioglitazone and troglitazone, bind to PPARy which is involved in transcription of genes regulating glucose and fat metabolism.
- LYN kinase activators such as tolimidone, potentiate insulin signaling.
- Another group of medicaments are the secretagogues, such as sulfonylureas (tolbutamide, acetohexamide, tolazamide, chlorpropamide, glipizide, glibenclamide, glimepiride, gliclazide, glycopyramide, gliquidone) and meglitinides (repaglinide and nateglinide) which increase insulin output from the pancreas.
- alpha-clucosidease inhibitors such as acarbose, miglitol and voglibose, which slow the digestion of starch in the small intestine, so that glucose from the starch of a meal enters the bloodstream more slowly, and can be matched more effectively by an impaired insulin response or sensitivity.
- Obesity is a complex multifactorial disease defined by excessive adiposity that can impair health and it is also one of the key risk factors for many diseases such as coronary heart disease, hypertension and stroke, certain types of cancer, type 2 diabetes, etc. In fact, obesity is the most important modifiable risk factor for type 2 diabetes.
- Body mass index (BMI) is a surrogate marker of adiposity calculated as weight (kg)/height 2 (m 2 ). The BMI categories for defining obesity vary by age and sex in infants, children and adolescents.
- obesity is defined by a BMI greater than or equal to 30 kg/m 2
- a BMI ranging from 25 to 29.99 kg/m 2 is also associated with increase disease risk and is referred to as pre-obesity or overweight.
- overweight is BMI-for-age greater than 1 standard deviation above the WHO Growth Reference median and obesity is greater than 2 standard deviations above the WHO Growth Reference median.
- overweight is weight-for- height greater than 2 standard deviations above WHO Child Growth Standards median whereas obesity is weight-for-height greater than 3 standard deviations above the WHO Child Growth Standards median.
- the main treatment for obesity consists of weight loss via calorie restricted dieting and physical exercise. The most effective treatment for obesity is bariatric surgery. Five medications have evidence for long-term use orlistat, lorcaserin, liraglutide, phentermine-topiramate, and naltrexone-bupropion. However, these drugs may have undesired side effects.
- a person is defined as having metabolic syndrome if having central obesity (generally defined as waist circumference with ethnicity specific values but, if BMI is >30kg/m 2 , central obesity can be assumed and waist circumference does not need to be measured) plus any two of the following four factors: raised triglycerides > 150 mg/dL (1.7 mmol/L) or specific treatment for this lipid abnormality; reduced HDL cholesterol ⁇ 40 mg/dL (1.03 mmol/L) in males ⁇ 50 mg/dL (1.29 mmol/L) in females or specific treatment for this lipid abnormality; raised blood pressure systolic BP > 130 or diastolic BP > 85 mm Hg or treatment of previously diagnosed hypertension; raised fasting plasma glucose (FPG) > 100 mg/dL (5.6 mmol/L), or previously diagnosed type 2 diabetes (if FPG is above 5.6 mmol/L or 100 mg/dL, OGTT is strongly recommended but is not necessary to define presence
- Metabolic syndrome is associated with the risk of developing cardiovascular disease and type-2 diabetes. Generally, the individual disorders that compose the metabolic syndrome are treated separately. Diuretics and ACE inhibitors may be used to treat hypertension. Various cholesterol medications may be useful if LDL cholesterol, triglycerides, and/or HDL cholesterol is abnormal. Dietary carbohydrate restriction reduces blood glucose levels, contributes to weight loss, and reduces the use of several medications that may be prescribed for metabolic syndrome.
- Nanoparticles are extensively used as carriers for oral drug delivery purposes.
- nanoparticles based on proteins show advantages for pharmaceutical applications due to their inherent biodegradabilidy, in vivo biocompatibility and, in general, lower cost than other materials such as polymers and lipids.
- Zein nanoparticles have demonstrated an important capability to extend the plasma levels of different drugs and other bioactive compounds by facilitating its absorption and improving their oral biovailability.
- WO 2012/007628 Al discloses the use of zein nanoparticles to encapsulate biologically active compounds.
- zein nanoparticles have been disclosed [D. Lucio et al., Eur. J. Pharm. Biopharm., 2017, 121, 104-112] as suitable oral carriers for glibenclamide, which is one of the drugs most commonly used for the treatment of diabetes.
- nanoparticles comprising a zein matrix and a basic amino acid, but which do not comprise any antidiabetic drug, such as glibenclamide, i.e. unloaded or empty nanoparticles, induced a significant reduction in blood glucose levels and fat accumulation in vivo.
- glibenclamide i.e. unloaded or empty nanoparticles
- These nanoparticles were also capable of delaying ageing and of increasing the lifespan in animal models.
- These nanoparticles also decreased significantly the accumulation of fat in obese animals, including visceral fat.
- these nanoparticles are suitable for the treatment and/or prevention of conditions related to high blood glucose levels and fat accumulation, such as diabetes, obesity and metabolic syndrome, and in extending the lifespan.
- the results obtained for the unloaded zein nanoparticles are particularly unexpected since free zein, i.e. where the protein does not form part of a nanoparticle, was not capable of producing the observed effects.
- the invention relates to a nanoparticle comprising a zein matrix and a basic amino acid for use in the treatment and/or prevention of a condition characterized by increased glucose levels and/or fat accumulation (such as diabetes, obesity and metabolic syndrome), wherein the nanoparticles does not comprise any biologically active ingredient.
- the invention in a second aspect, relates to a composition
- a composition comprising at least one nanoparticle as defined in the first aspect and a pharmaceutically acceptable excipient for use in the treatment and/or prevention of a condition characterized by increased glucose levels and/or fat accumulation (such as diabetes, obesity and metabolic syndrome).
- the invention relates to the use of a nanoparticles as defined in the first aspect in the manufacture of a medicament for the treatment and/or prevention of a condition characterized by increased glucose levels and/or fat accumulation (such as diabetes, obesity and metabolic syndrome).
- the invention relates to the use of a composition comprising at least one nanoparticles as defined in the first aspect and a pharmaceutically acceptable excipient in the manufacture of a medicament for the treatment and/or prevention of a condition characterized by increased glucose levels and/or fat accumulation (such as diabetes, obesity and metabolic syndrome).
- the invention relates to a method of treatment and/or prevention of a condition characterized by increased glucose levels and/or fat accumulation (such as diabetes, obesity and metabolic syndrome) comprising administering to a subject in need thereof a nanoparticle as defined in the first aspect.
- the invention in a sixth aspect, relates to a method of treatment and/or prevention of a condition characterized by increased glucose levels and/or fat accumulation (such as diabetes, obesity and metabolic syndrome) comprising administering to a subject in need thereof a composition comprising at least one nanoparticle as defined in the first aspect and a pharmaceutically acceptable excipient
- the invention relates to the non-therapeutic use of a nanoparticle as defined in the first aspect for extending the lifespan of an organism.
- the invention relates to the non-therapeutic use of a composition comprising at least a nanoparticle as defined in the first aspect and a carrier acceptable in food or nutraceutics, for extending the lifespan of an organism.
- the invention relates to a nanoparticle comprising a zein matrix, a basic amino acid and polyethylene glycol or a derivative thereof for use in the treatment and/or prevention of a condition characterized by increased glucose levels and/or fat accumulation (such as diabetes, obesity and metabolic syndrome).
- a composition comprising at least one nanoparticle as defined in the ninth aspect and a pharmaceutically acceptable excipient for use in the treatment and/or prevention of a condition characterized by increased glucose levels and/or fat accumulation (such as diabetes, obesity and metabolic syndrome).
- the invention relates to the use of a nanoparticles as defined in the ninth aspect in the manufacture of a medicament for the treatment and/or prevention of a condition characterized by increased glucose levels and/or fat accumulation (such as diabetes, obesity and metabolic syndrome).
- the invention relates to the use of a composition comprising at least one nanoparticles as defined in the ninth aspect and a pharmaceutically acceptable excipient in the manufacture of a medicament for the treatment and/or prevention of a condition characterized by increased glucose levels and/or fat accumulation (such as diabetes, obesity and metabolic syndrome).
- the invention relates to a method of treatment and/or prevention of a condition characterized by increased glucose levels and/or fat accumulation (such as diabetes, obesity and metabolic syndrome) comprising administering to a subject in need thereof a nanoparticle as defined in the ninth aspect.
- the invention relates to a method of treatment and/or prevention of a condition characterized by increased glucose levels and/or fat accumulation (such as diabetes, obesity and metabolic syndrome) comprising administering to a subject in need thereof a composition comprising at least one nanoparticle as defined in the ninth aspect and a pharmaceutically acceptable excipient.
- the invention relates to the non-therapeutic use of a nanoparticle as defined in the ninth aspect for extending the lifespan of an organism.
- the invention relates to the non-therapeutic use of a composition comprising at least a nanoparticle as defined in the ninth aspect and a carrier acceptable in food or nutraceutics, for extending the lifespan of an organism.
- Figure 1 shows the Scanning Electron Microscopy (SEM) images of spray-dried nanoparticles.
- A naked nanoparticles (NP);
- B PEG-coated nanoparticles at a PEG-to- zein ratio of 0.5 (NP50).
- NP50 PEG-to- zein ratio of 0.5
- Figure 5 shows the effect of the different formulations over the fat accumulation of C. elegans.
- NGM nematode growth medium (negative control); Orl: orlistat (positive control); Free zein: zein in purified water; NP: naked empty zein nanoparticles; NP50: empty zein nanoparticles coated with PEG at a PEG-to-zein ratio of 0.5.
- Data expressed as mean ⁇ SD (n 3 wells with at least 25 worms/well). *: p ⁇ 0.05; **: p ⁇ 0.01 compared to control. #: p ⁇ 0.05; ##: p ⁇ 0.01 compared to free zein.
- Control untreated worms; NP (LI worms treated from LI larvae stage until 18 th -day adulthood, NP (L4 ->): worms treated from 1-day adult until 18 th -day adulthood.
- Figure 7 shows the effects of zein nanoparticles (NP) treatment on the expression of genes in wild-type N2 strain C. elegans.
- NP zein nanoparticles
- Figure 8 shows the effect of the different treatments over the blood glucose levels of healthy male Wistar rats.
- Control receiving water; Free zein: suspension of pure zein in water; NP: naked zein nanoparticles; NP50: zein nanoparticles coated with PEG at a PEG- to-zein ratio of 0.5. All the treatments administered at a dose of 50 mg/kg.
- Data expressed as mean ⁇ SD (n 6). *: p ⁇ 0.05; **: p ⁇ 0.01 compared to control. #: p ⁇ 0.05; ##: p ⁇ 0.01 compared to free zein, f : p ⁇ 0.05; f f : p ⁇ 0.01 compared to NP.
- Figure 9 shows the effect of the oral administration of zein nanoparticles on the blood levels of insulin (A) and GLP-1 (B) in healthy male Wistar rats.
- Control animals receiving water.
- NP naked zein nanoparticles;
- NP50 zein nanoparticles coated with PEG at a PEG-to-zein ratio of 0.5. All the treatments administered at a dose of 50 mg/kg.
- Data expressed as mean ⁇ SD (n 6). *: p ⁇ 0.05; **: p ⁇ 0.01 compared to control. #: p ⁇ 0.05.
- Figure 10 shows the effect of the different treatments over the blood glucose levels of healthy male Wistar rats after an intraperitoneal injection of glucose (2 g/kg). All the treatments were administered orally at a dose of 50 mg/kg.
- Control animals receiving water; Free zein: zein in purified water; NP50: empty zein nanoparticles coated with PEG at a PEG-to-zein ratio of 0.5. All the treatments administered at a dose of 50 mg/kg.
- Data expressed as mean ⁇ SD (n 6). *: p ⁇ 0.05; **: p ⁇ 0.01 compared to control. #: p ⁇ 0.05 compared to NP.
- Figure 12 represents the analysis of the body composition of the obese rats after 6 weeks of administration.
- A Proportion of fat mass relative to the body weight of each rat;
- B Ratio between the amount of fat mass and lean mass (fat mass/lean mass of each individual rat) at the end of the experiment.
- SC animals fed with standard control diet (2014 Teklad global 14% protein rodent maintenance diets);
- HFS animals fed with high fat/high sucrose (HFS) diet (D12451 - rodent diet);
- HFS-NP animals fed with HFS supplemented with zein nanoparticles.
- Figure 13 represents the effect of supplementation of HFS-fed animals with zein nanoparticles on the retroperitoneal (A), epididymal (B), visceral (C) and subcutaneous (D) fat weight.
- SC animals fed with standard control diet (2014 Teklad global 14% protein rodent maintenance diets);
- HFS animals fed with high fat/high sucrose (HFS) diet (D12451 - rodent diet);
- HFS-NP animals fed with HFS supplemented with zein nanoparticles.
- Figure 14 represents the effect of supplementation of HFS-fed animals with zein nanoparticles during 6 weeks on their serum lipid profile.
- A Triglycerides (TAG),
- B HDL-Cholesterol,
- C Total cholesterol and
- D Atherogenic index.
- SC animals fed with standard control diet (2014 Teklad global 14% protein rodent maintenance diets);
- HFS animals fed with high fat/high sucrose (HFS) diet (D12451 - rodent diet);
- HFS-NP animals fed with HFS supplemented with zein nanoparticles.
- Figure 15 represents the effect of supplementation of HFS-fed animals with zein nanoparticles on the plasma levels of the cytokine MCP-1 (Monocyte Chemoattractant Protein-1).
- SC animals fed with standard control diet (2014 Teklad global 14% protein rodent maintenance diets);
- HFS animals fed with high fat/high sucrose (HFS) diet (D12451 - rodent diet);
- HFS-NP animals fed with HFS supplemented with zein nanoparticles.
- Figure 16 shows the effect of supplementation of HFS-fed animals with zein nanoparticles on lipid steatosis.
- SC animals fed with standard control diet (2014 Teklad global 14% protein rodent maintenance diets);
- HFS animals fed with high fat/high sucrose (HFS) diet (D12451 - rodent diet);
- HFS-NP animals fed with HFS supplemented with zein nanoparticles.
- nanoparticles comprising a zein matrix and a basic amino acid and which do not comprise any biologically active ingredient
- the first aspect of the present invention is directed to a nanoparticle comprising a zein matrix and a basic amino acid for use in the treatment and/or prevention of a condition characterized by increased glucose levels and/or fat accumulation, wherein the nanoparticle does not comprise any biologically active ingredient.
- This aspect may also be worded as the use of a nanoparticle comprising a zein matrix and a basic amino acid in the manufacture of a medicament for the treatment and/or prevention of a condition characterized by increased glucose levels and/or fat accumulation, wherein the nanoparticle does not comprise any biologically active ingredient.
- nanoparticle comprising a zein matrix and a basic amino acid, wherein the nanoparticle does not comprise any biologically active ingredient.
- nanoparticle refers to colloidal systems of the type of spheres or similar shapes with an average size less than 1 micrometer (pm).
- the nanoparticles are characterized by having an average particle size less than 1 pm, typically comprised between 1 and 999 nm, preferably between 10 and 900 nm, more preferably between 50 and 500 nm, more preferably between 100 and 450 nm, even more preferably between 140 and 400 nm, even more preferably between 150 and 300 nm, still more preferably from 150 to 250 nm.
- average size refers to the average diameter of the population of nanoparticles which move together in an aqueous medium.
- the average size of these systems can be measured by standard processes known by the person skilled in the art, and which are described, for example, in the experimental part (see below).
- zein includes any globular protein belonging to the group of prolamines; said protein is generally synthesized during the development of the endosperm (nutritive tissue formed in the embryo sac of seed plants and usually forms a food deposit for the embryo of the seeds of various angiosperm plants). Zein can be obtained from any suitable source, although it is preferably obtained from corn. Various methods and techniques for extracting zein from com endosperm are known; commercial zein is generally extracted from corn gluten meal (US 2009/0258050).
- zein The study of zein reveals an extreme variability at the genetic level and, therefore, a complex situation among the different proteins forming part of the group of proteins known as zeins.
- Native zein is actually a large and heterogeneous family of several groups of proteins which differ in their molecular size, solubility, and charge. More than twenty different zein have been estimated to exist.
- the analysis of zein extracts by means of high-performance liquid chromatography (HPLC), ion-exchange chromatography, gel exclusion chromatography, SDS-polyacrylamide gel electrophoresis (SDS-PAGE), isoelectric focusing (IEF), amino acid analysis, and DNA cloning techniques have led to a better understanding of zein proteins.
- composition of the amino acids of zein reveals a large amount of leucine, alanine, glutamine, and phenylalanine; however, lysine and tryptophan are absent or, alternatively, are present in very small amounts.
- the high proportion of non-polar amino acid residues and the exceptional lack of ionic groups are responsible for the hydrophobic nature thereof and for the particular solubility thereof.
- the protein bodies of zein are formed by three types of structurally different proteins: alpha-zein (a-zein), gamma-zein (y-zein) [which includes beta zein (0-zein)], and deltazein (6-zein). Said proteins can be classified into four classes (a-zein, 0-zein, y-zein and 6-zein) based on the differences in solubility and sequence.
- a-zein Zein extracted without reducing agents forms a large multigene family of polypeptides referred to as a-zein.
- a-zeins generally the most abundant fraction of native zein, contain about 40 amino acids in the amino terminus which precede a series of 9 or 10 repeated peptides of 20 amino acids. These repeats are believed to be a-helices and wind the protein into a rod-shaped molecule.
- the other fractions of zein (0-, y-, and 6-zein) must be extracted using alcohols solutions of alcohols containing reducing agents to break the disulfide bonds.
- mercaptoethanol is used for laboratory extraction.
- 0-, y-, and 6-zeins show no sequence homology with a-zein.
- y-Zein is soluble in both aqueous and alcoholic solvents in reducing conditions.
- Each of the y-zeins has a unique N-terminus sequence. By way of example, in the 50 kDa y-zein, this region is 136 amino acids long and it is very rich in histidine.
- the 27 kDa y-zein has a series of eight tandem repeats of a hexapeptide which produce 11 amino acids after the amino terminus.
- the first eight amino acids of the 16 kDa y-zein protein are identical to those of the 27 kDa y-zein, but the 16 kDa y-zein has three degenerate versions of prolinerich repeats.
- y-Zein normally represents between 10 and 15% of the total of the zeins.
- P-Zein which is related to y-zein, includes a methionine-rich 17 kDa polypeptide and constitutes up to 10% of the total zein. Approximately the last 140 amino acids of P- and y-zeins are 85% identical. P-Zein has no repetitive peptides and seems to mostly consist of P-sheets and turn conformation.
- 6-zein is a 10 kDa protein and is a minor fraction of zein. 6-zeins are the most hydrophobic of the group, contain no repetitive peptides, and are exceptionally methionine- and cysteine-rich.
- GRAS Generally Recognized as Safe
- the source or the grade of zein is not limited to a single zein and, in fact, any zein can be used to put the present invention into practice.
- the commercial zeins which can be used in the present invention include, but are not limited to, the zein supplied by Sigma-Aldrich (product number Z 3625); Wako Puras Chemical Industries (product numbers 261-00015, 264-01281 and 260-01283); Spectrum Chemical (product numbers Z1131 and ZE105); ScienceLab units SLZ1150; SJZ Chem-Pharma Company (product name ZEIN (GLIDZIN); Arco Organics (catalog numbers 17931-0000, 17931-1000, and 17931-5000); and Freeman Industries, zein regular grade F4000, zein regular grade F4400, zein special grade F6000, etc.
- the commercial zein supplied by Sigma- Aldrich (product number Z 3625), obtained from corn, is used.
- zein includes both native zein and modified zein.
- modified zein includes any zein having an amino acid sequence which is normally not naturally-occurring, but which behave similarly to authentic zeins and which are soluble in alcohol. Amino acid substitutions, especially those which do not substantially modify the hydrophobicity, may be introduced. By way of illustration, amino acid substitutions can be performed within the repeated sections, or a single amino acid can be substituted, and substitutions can also be performed in the segments connecting the domains of repeated sequences.
- Insertions and substitutions can also be introduced in the carboxyl terminus and the amino terminus of the zein molecule. Additionally, deletions can be performed in the amino acid sequence provided that the resulting protein is functionally equivalent to zein, i.e., that it maintains its properties.
- any zein can form the matrix of the nanoparticle; nevertheless, in a particular embodiment, said zein is a zein from corn, such as the zein supplied by Sigma-Aldrich (product number Z 3625).
- matrix nanoparticle systems also known as nanospheres
- the polymer or macromolecule i.e. zein
- the nanoparticles comprise a basic amino acid.
- a “basic amino acid” refers to an organic molecule containing an amino group (-NH2) and a carboxyl group (- COOH) and positive charge.
- the basic amino acid of the nanoparticles for use of the invention refers to a free amino acid that is not covalently bonded to any other atom, i.e. it does not form part of any oligomeric, peptidic or other molecular structures, but refers to the amino acid as being an independent molecule.
- Said basic amino acid is preferably a basic alpha-amino acid such as lysine, arginine, histidine or mixtures thereof.
- the basic amino acid present in the nanoparticles of the invention is lysine.
- the weight ratio of zein to basic amino acid is in the range of from 0.01 : 1 to 50: 1, preferably from 0.5: 1 to 25: 1, more preferably from 1 : 1 to 20: 1, more preferably from 5: 1 to 15: 1, even more preferably from 6: 1 to 7: 1, still more preferably about 6.7: 1.
- the nanoparticles are able to diffuse through the mucus layer, improving the absorption through the oral mucosa.
- the biological activity of the nanoparticles described herein is achieved in the absence of any pharmaceutically active ingredients used for the treatment of diabetes.
- the nanoparticles do not comprise any biologically active ingredient.
- biologically active ingredient refers to any compound having therapeutic activity.
- biologically active ingredients include antidiabetic drugs, statins, ACE inhibitors, angiotensin receptor blockers, B- receptor blockers, a blockers, calcium channel blockers, diuretics, aldosterone inhibitors, anticoagulants, heparin, antiplatelet drugs, fibrinolytics, anti-hemophilic factors, haemostatic drugs, antimicrobial agents, antipyretics, analgesics, antimalarial drugs, antibiotics, antiseptics, hormone replacements, antacids, reflux suppressants, antiflatulents, antidopaminergics, proton pump inhibitors, FL-receptor antagonists, cytoprotectants, prostaglandin analoges, laxatives, antispasmodics, antidiarrheals, bile acid sequestrants, opioids, cardiac glycosides, antiarrhythmics, nitrate
- antidiabetic drugs are sulfonylureas (such as, tolbutamide, acetohexamide, tolazamide, chlorpropamide, glipizide, glimepiride, gliclazide, glycopyramide, gliquidone), bisguanides (such as metformin, phenformin and buformin), thiazolidinediones (such as rosiglitazone, pioglitazone and troglitazone), LYN kinease activators LYN (such as tolimidone), meglitinides (such as repaglinide and nateglinide), alpha-glucosidease inhibitors (such as acarbose, miglitol and voglibose), GLP-1 agonists (such as exenatide, dulaglutide, semaglutide, liraglutide and lixisenatide), DPP-4 inhibitors (such as saxagliptin
- Examples of antidiabetic drugs of phytochemical origin which are commonly used for the treatment and/or prevention of diabetes such as quercetin, berberina, rutin, fisetin, kaempferol, isorhamnetin, morin, hesperidin, naringenin, eriodictyol, apigenin, luteolin, tangerein, chrysin, wogonin, diosmin, baicalein, genistein, daidzein, myrecelin, curcumin, resveratrol, cyaniding, delphinidin, pelargonidin, glycan (Gymnema sylvestre), 1-DOPA (Mucana Prune ns). vasicine, vasicinone and moran A.
- the nanoparticles do not comprise PVM/MA.
- poly (methyl vinyl ether-co-maleic anhydride) refers to the copolymer of methyl vinyl ether and maleic anhydride (commercialized by International Specialty Products, ISP, under trademark Gantrez®AN). Therefore expressions, “PVM/MA”, poly(anhydride), or Gantrez® AN are synonyms, and are indistinctly used in this description.
- Gantrez® AN copolymer contains alternating units of methylvinylether and maleic anhydride, having the formula:
- the fundamental character of this polymerization requires that a maleic anhydride unit must be adjacent to a methylvinylether unit and vice versa, resulting in a true alternating copolymer.
- the anhydride groups in Gantrez® AN structure allows the chemical interaction of this polymer with hydroxyl containing molecules through a nucleophilic substitution reaction mechanism.
- the nanoparticles used in this aspect of the invention do not comprise a polyethylene glycol polymer or derivative thereof. Polyethylene glycol polymers and derivatives thereof are defined below.
- the nanoparticles consist of a zein matrix and a basic amino acid as previously defined.
- nanoparticles defined herein can be formulated in a composition.
- another aspect of the invention relates to a composition comprising at least one nanoparticle as defined in the first aspect and a pharmaceutically acceptable carrier for use in the treatment and/or prevention of a condition characterized by increased glucose levels and/or fat accumulation.
- composition comprising at least one nanoparticle as defined in the first aspect and a pharmaceutically acceptable excipient in the manufacture of a medicament for the treatment and/or prevention of a condition characterized by increased glucose levels and/or fat accumulation.
- composition comprising at least one nanoparticle as defined in the first aspect and a pharmaceutically acceptable excipient.
- compositions comprises a plurality of said nanoparticles.
- Said nanoparticles can be presented in the form of a suspension, preferably in an aqueous medium, or, alternatively, they can be presented in the form of a dry powder, for example as a lyophilizate together with a cryoprotective agent
- compositions are well known in the pharmaceutical art, and are described, for example, in Remington: The Science and Practice of Pharmacy, Lippincott Williams and Wilkins (22 nd Ed., 2012). The choice of pharmaceutical excipient can be selected with regard to the intended route of administration and standard pharmaceutical practice.
- the pharmaceutical composition of the invention may be formulated in a solid (for example, tablets, capsules, coated tablets, granulates, suppositories, sterile crystalline or amorphous solids which can be reconstituted to provide liquid forms, etc.), liquid (for example suspension or dispersion of the nanoparticles, etc.) or semisolid (gels, pomades, creams and the like) pharmaceutical dosage form.
- a solid for example, tablets, capsules, coated tablets, granulates, suppositories, sterile crystalline or amorphous solids which can be reconstituted to provide liquid forms, etc.
- liquid for example suspension or dispersion of the nanoparticles, etc.
- semisolid gels, pomades, creams and the like
- the described compositions will comprise suitable carriers or vehicles for each formulation.
- the pharmaceutical composition can contain, as appropriate, stabilizers, suspensions, preservatives, surfactants and the like. These excipients will be chosen according to the selected pharmaceutical dosage form.
- said pharmaceutical composition is formulated as a pharmaceutical dosage form suitable for its administration by a route of access to mucosae.
- the pharmaceutical composition provided by this invention is orally administered; therefore the carrier or vehicle comprises one or more pharmaceutical excipients acceptable for the administration by oral route.
- Oral formulations are conventionally prepared by methods known by persons skilled in the art. A review of the different forms of administration of active ingredients, of the excipients to be used, and of the processes for manufacturing them can be found in the book “Tratado de Tecnologia Farmaceutica”, Volume III, by Ramon Martinez Pacheco, (2017), Ed. Sintesis, Madrid; and “Pharmaceutics: The Science of Dosage Form Design”, by Michael E. Aulton, 2 nd ed. 2001, Elsevier, ISBN-13: 978-0443055171.
- the nanoparticles and compositions described above are for the treatment and/or prevention of a condition characterized by increased glucose levels and/or fat accumulation, such as diabetes, obesity and metabolic syndrome.
- nanoparticles and compositions described above are for the treatment and/or prevention of diabetes, preferably for the treatment and/or prevention of prediabetes or type-2 diabetes, more preferably for the treatment and/or prevention of prediabetes.
- type-2 diabetes occurs when the body becomes resistant to insulin or there is not enough insulin produced. This type of diabetes is largely the result of excess body weight and physical inactivity. It is characterized by at least one of the following blood glucose levels: fasting plasma glucose level > 7.0 mmol/L (126 mg/dL) or plasma glucose > 11.1 mmol/L (200 mg/dL) two hours after a 75 g oral glucose load as in a glucose tolerance test.
- a prediabetic state or prediabetes is characterized by impaired fasting glucose levels and/or impaired glucose tolerance.
- Impaired fasting glucose levels are from 6.1 to 6.9 mmol/L (110 to 125 mg/dL).
- Impaired glucose tolerance is defined by a plasma glucose at or above 7.8 mmol/L (140 mg/dL), but not over 11.1 mmol/L (200 mg/dL), two hours after a 75 gram oral glucose load.
- the nanoparticles and compositions described above are for the treatment and/or prevention of obesity.
- BMI Body mass index
- the BMI categories for defining obesity vary by age and sex in infants, children and adolescents. For adults, obesity is defined by a BMI greater than or equal to 30 kg/m 2 A BMI ranging from 25 to 29.99 kg/m 2 is also associated with increase disease risk and is referred to as pre-obesity or overweight.
- nanoparticles and compositions described above are for the treatment and/or prevention of metabolic syndrome.
- a person is defined as having metabolic syndrome if having central obesity (generally defined as waist circumference with ethnicity specific values but, if BMI is >30kg/m 2 , central obesity can be assumed and waist circumference does not need to be measured) plus any two of the following four factors: raised triglycerides > 150 mg/dL (1.7 mmol/L) or specific treatment for this lipid abnormality; reduced HDL cholesterol ⁇ 40 mg/dL (1.03 mmol/L) in males ⁇ 50 mg/dL (1.29 mmol/L) in females or specific treatment for this lipid abnormality; raised blood pressure systolic BP > 130 or diastolic BP > 85 mm Hg or treatment of previously diagnosed hypertension; raised fasting plasma glucose (FPG) > 100 mg/dL (5.6 mmol/L), or previously diagnosed type 2 diabetes (if FPG is above 5.6 mmol/L or 100 mg/dL, OGTT is strongly recommended but is not
- treat refers to reducing the potential for a certain disease or disorder, reducing the occurrence of a certain disease or disorder, and/or a reduction in the severity of a certain disease or disorder, preferably, to an extent that the subject no longer suffers discomfort and/or altered function due to it. It also refers to mitigating or decreasing at least one clinical symptom and/or inhibition or delay in the progression of the condition and/or prevention or delay of the onset of a disease or illness.
- prevention refers to avoiding the appearance of a certain disease or disorder.
- the prevention can be complete (e.g. the total absence of a disease).
- the prevention can also be partial, such that for example the occurrence of a disease in a subject is less than that which would have occurred without the administration of the combination or composition of the present invention.
- Prevention also refers to reduced susceptibility to a clinical condition.
- the prevention also includes reducing the risk of suffering the disease.
- nanoparticles of the invention to be administered to a subject in need of treatment and/or prevention with the nanoparticles should be sufficient to trigger a beneficial therapeutic response in the patient over time.
- nanoparticles are administered to a patient in an amount sufficient to prevent, alleviate, reduce, cure or at least partially arrest symptoms and/or complications from the disease.
- An amount adequate to accomplish this is defined as a “therapeutically effective dose”.
- the dose can vary within a broad range, and will depend, for example on the frequency of administration and on the potency and duration of action, on the nature and severity of the disease and symptoms, and on the sex, age, weight, co-medication and individual responsiveness of the subject to be treated and on whether the therapy is acute or prophylactic.
- the dose of the nanoparticles to be administered to a subject may be comprised, for example, between approximately 0.1 and approximately 50 mg per kg of body weight, preferably, between 0.1 and 10 mg per kg of body weight.
- the subject to which the nanoparticles are administered is a human or animal; preferably subjects are mammals, more preferably humans.
- the further aspect of the present invention is directed to the non-therapeutic use of a nanoparticle comprising a zein matrix and a basic amino acid and which does not comprise any biologically active ingredient, as defined above, for extending the lifespan of an organism.
- the nanoparticles used in this aspect of the invention are as those described above for the first aspect.
- the nanoparticles used in this aspect of the invention are characterized by having an average particle size less than 1 pm, typically comprised between 1 and 999 nm, preferably between 10 and 900 nm, more preferably between 50 and 500 nm, more preferably between 100 and 450 nm, even more preferably between 140 and 400 nm, even more preferably between 150 and 300 nm, still more preferably from 150 to 250 nm.
- any zein can form the matrix of the nanoparticles used in this aspect of the invention; nevertheless, in a particular embodiment, said zein is a zein from corn, such as the zein supplied by Sigma-Aldrich (product number Z 3625).
- the basic amino acid present in the nanoparticles is as previously described.
- the basic amino acid of the nanoparticles used in this aspect of the invention is selected from the group consisting of lysine, arginine, histidine and mixtures thereof, preferably lysine.
- the weight ratio of zein to basic amino acid is in the range of from 0.01 : 1 to 50: 1, preferably from 0.5: 1 to 25: 1, more preferably from 1: 1 to 20:1, more preferably from 5:1 to 15:1, even more preferably from 6: 1 to 7: 1, still more preferably about 6.7: 1.
- the nanoparticles used in this aspect of the invention do not comprise a polyethylene glycol polymer or derivative thereof.
- nanoparticles used in this aspect of the invention do not comprise any biologically active ingredient, as defined above. More particularly, the nanoparticles used in this aspect consist of the zein matrix and the basic amino acid.
- the nanoparticles do not comprise PVM/MA.
- PVM/MA is as previously defined.
- the nanoparticles used in this aspect of the invention can be formulated in a composition.
- another aspect of the invention relates to the non-therapeutic use of a composition comprising at least one nanoparticle as defined herein and an excipient acceptable in food or nutraceutics, for extending the lifespan of an organism. Said composition comprises a plurality of said nanoparticles.
- said nanoparticles can be presented in the form of a suspension, preferably in an aqueous medium, or, alternatively, they can be presented in the form of a dry powder, for example as a lyophilizate together with a cryoprotective agent.
- compositions for use according to this aspect are a food, or nutraceutical product.
- the product is a food, a feed or a food for special medical purposes comprising the nanoparticles described herein and a food acceptable vehicle or carrier.
- the term “food” is any substance or product of any nature, solid or liquid, natural or processed which due to its characteristics, applications, components, preparation and state of preservation, can usually or ideally be used for some of the following purposes: a) as normal nutrition for human beings or animals or as pleasurable foods; or b) as dietetic products, in special cases of human or animal food.
- feed includes all the natural materials and finished products of any origin which, separately or conveniently mixed with one another, are suitable as animal food. Examples include cattle feed, chicken feed, horse feed, poultry feed.
- food for special medical purposes means foods specially processed or formulated and intended for the dietary management of people with certain diseases, disorders or medical conditions. These special foods are intended for people whose nutritional requirements cannot be met by normal foods. In particular, they are intended for the exclusive or partial feeding of patients with a limited, impaired or disturbed capacity to take, digest, absorb, metabolise or excrete ordinary food or certain nutrients contained therein, or metabolites, or with other medically-determined nutrient requirements, whose dietary management cannot be achieved by modification of the normal diet alone, with other food intended for a particular diet, or both. Food for special medical purposes are to be used under the supervision of a medical practitioner and other appropriate health professionals.
- a ready-to-eat food is that which does not need to be diluted by means of an aqueous solution suitable for consumption for example.
- the ingredients present in a ready-to-eat food are balanced and there is no need to add additional ingredients to the food to make it ready to eat, such considered by a person skilled in the art.
- a concentrated food is that in which one or more ingredients are present at a higher concentration than in a ready-to-eat food, therefore for use it is necessary to dilute it by means of an aqueous solution suitable for consumption for example.
- Non-limiting, illustrative examples of foods provided by this invention include both dairy products and derivatives, for example, fermented milks, yoghurt, kephir, curd, cheeses, butters, ice creams, milk-based desserts, etc., and non-dairy products, such as baked products, cakes and pastries, cereals, chocolates, jams, juices, other fruit derivatives, oils and margarines, prepared dishes, etc.
- the product is a nutraceutical product comprising the nanoparticles described herein and a nutraceutical acceptable carrier.
- the product is nutraceutical product comprising the nanoparticles described herein and a nutraceutical acceptable vehicle or carrier.
- the term “nutraceutical product” refers to a product suitable for use in human beings or animals, comprising one or more natural products with therapeutic action which provide a health benefit or have been associated with disease prevention or reduction, for example, it includes food supplements or dietary supplements presented in a non-food matrix (e.g., capsules, powder, etc.) of a concentrated natural bioactive product usually present (or not) in the foods and which, when taken in a dose higher than that existing in those foods, exerts a favorable effect on health which is greater than effect which the normal food may have.
- a non-food matrix e.g., capsules, powder, etc.
- the term “nutraceutical product” includes isolated or purified food products as well as additives or food supplements which are generally presented in dosage forms normally used orally, for example, capsules, tablets, sachets, drinkable phials, etc.; such products provide a physiological benefit or protection against diseases, generally against chronic diseases.
- the nutraceutical product provided by the invention can contain one or more nutraceuticals (products or substances associated with disease prevention or reduction), for example, flavonoids, omega-3 fatty acids, etc., and/or one or more prebiotics (non-digestible food ingredients which stimulate probiotic activity and/or growth), for example, oligofructose, pectin, inulin, galactooligosaccharides, lactulose, human milk oligosaccharides, dietary fiber, etc.
- nutraceuticals products or substances associated with disease prevention or reduction
- prebiotics non-digestible food ingredients which stimulate probiotic activity and/or growth
- oligofructose for example, pectin, inulin, galactooligosaccharides, lactulose, human milk oligosaccharides, dietary fiber, etc.
- excipient can be selected with regard to the type of composition or product, the intended route of administration and standard practice.
- composition of the invention may be formulated as a liquid, semi-solid or solid form.
- said composition is formulated as a dosage form suitable for its administration by a route of access to mucosae.
- the composition provided by this invention is orally administered; therefore the carrier or vehicle comprises one or more excipients acceptable for the administration by oral route.
- the organisms to which the nanoparticles are administered are preferably mammals, more preferably humans.
- the term “extending the lifespan of an organism” refers to increasing the lifespan of an organism relative to the lifespan in the absence of the nanoparticles (e.g., relative to the projected lifespan of an individual, a population, an individual with certain diseases or lifestyle choices, etc.).
- said increase in the lifespan is considered as being suitable, preferably said increase in the lifespan is of at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70% or at least 80% with respect to the projected lifespan in the absence of the nanoparticles.
- the increase in the lifespan is from 10% to 50%.
- said increase in the lifespan is characterized by a reduction of the glucose levels, fat accumulation and/or intracellular ROS levels in the organism to which the nanoparticles are administered.
- nanoparticles comprising a zein matrix, a basic amino acid and polyethylene glycol or a derivative thereof
- the further aspect of the present invention is directed to a nanoparticle comprising a zein matrix, a basic amino acid and polyethylene glycol or a derivative thereof for use in the treatment and/or prevention of a condition characterized by increased glucose levels and/or fat accumulation.
- This aspect may also be worded as the use of a nanoparticle comprising a zein matrix, a basic amino acid and polyethylene glycol or a derivative thereof in the manufacture of a medicament for the treatment and/or prevention of a condition characterized by increased glucose levels and/or fat accumulation.
- a method of treatment and/or prevention of a condition characterized by increased glucose levels and/or fat accumulation comprising the administration of a nanoparticle comprising a zein matrix, a basic amino acid and polyethylene glycol or a derivative thereof.
- nanoparticle is as previously defined and are characterized by having an average particle size less than 1 pm, typically comprised between 1 and 999 nm, preferably between 10 and 900 nm, more preferably between 50 and 500 nm, more preferably between 100 and 450 nm, even more preferably between 140 and 400 nm, even more preferably between 150 and 300 nm, still more preferably from 150 to 250 nm.
- zein is as previously defined. Virtually any zein can form the matrix of the nanoparticle for use of the invention; nevertheless, in a particular embodiment, said zein is a zein from com, such as the zein supplied by Sigma- Aldrich (product number Z 3625).
- matrix nanoparticle systems also known as nanospheres
- the polymer or macromolecule i.e. zein
- the nanoparticles comprise a basic amino acid, as previously defined.
- Said basic amino acid is preferably a basic alpha-amino acid such as lysine, arginine, histidine or mixtures thereof.
- the basic amino acid present in the nanoparticles of the invention is lysine.
- the weight ratio of zein to basic amino acid is in the range of from 0.01 : 1 to 50: 1, preferably from 0.5: 1 to 25: 1, more preferably from 1 : 1 to 20: 1, more preferably from 5: 1 to 15: 1, even more preferably from 6: 1 to 7: 1, still more preferably about 6.7: 1.
- the nanoparticle further comprises a polyethylene glycol or derivative thereof. These particles are also named PEGylated nanoparticles.
- polyethylene glycol (PEG) is understood to be any hydrophilic polymer soluble in water containing ether groups linked by 2 carbon atoms, optionally branched ethylene groups. Therefore this definition includes branched or nonbranched polyethylene glycols.
- PEG is also known as polyethylene oxide (PEO) or polyoxyethylene (POE) (the three names are chemically synonymous and refers to an oligomer or polymer of ethylene oxide).
- PEO polyethylene oxide
- POE polyoxyethylene
- the term also includes derivatives of one of the terminal hydroxyl groups, which can be modified (one of two ends).
- polyethylene glycol derivatives maintaining one primary hydroxy (-OH) group can be used.
- Polyethylene glycols are water-soluble polymers that have been approved (FDA) for the oral, parenteral and topical administration of drugs.
- Polyethylene glycols are produced by means of polymerization of ethylene oxide (EO) in the presence of water, monoethylene glycol or di ethylene glycol as reaction initiators in an alkaline medium
- EO ethylene oxide
- monoethylene glycol or di ethylene glycol as reaction initiators in an alkaline medium
- the polymerization reaction ends by neutralizing the catalyst with an acid (lactic acid, acetic acid or the like).
- an acid lactic acid, acetic acid or the like
- n is the number of EO monomers or units.
- polyethylene glycol is normally used to indicate the significant influence of hydroxyl terminal groups on the physicochemical properties of these molecules.
- PEG is normally used in combination with a numerical value. In the pharmaceutical industry the number indicates the average molecular weight, whereas in the cosmetic industry the number accompanying the letters PEG refers to the polymerized EO units forming the molecule (Handbook of Pharmaceutical Excipients, Rowev R.C., Sheskey P. J., Weller P. J. (Eds.), 4 th Edition, Pharmaceutical Press and American Pharmaceutical Association, London, UK, 2003).
- PEGs are included in various pharmacopeias, although the nomenclature differs (International Harmonisation: Polyethylene glycol (PEG): Pharmeuropa 1999, 11, 612-614). According to the Handbook of Pharmaceutical Excipients (Fourth Edition), 2003 Edited by R.C. Rowe, P.J. Sheskey and P.J. Weller Published by the Pharmaceutical Press (London, UK) and the American Pharmaceutical Association (Washington, USA), polyoxyethylene glycols are also referred to as polyethylene glycols, macrogols, or PEG. The British and European Pharmacopoeias use polyethylene glycols and macrogols, while the US pharmacopoeia (USP) uses polyethylene glycols. In the present invention, the number accompanying the letters PEG refers to the average molecular weight.
- molecular weight is defined as the average molar mass of a molecule. Unlike small molecules, the molecular weight of a polymer is not one unique value. Rather, a given polymer will have a distribution of molecular weights depending for example on the way the polymer is produced. Therefore, as it is used herein, the term molecular weight for polymers refers to the distribution of molecular weight, or of the average molecular weight.
- the average molecular weight of PEG may be determined by conventional methods in the art, such as 1 H-RMN, size exclusion chromatography (SEC), or based on the hydroxyl value, as described, by way of illustration, in Yoncheva K., et al.
- the polyethylene glycols used preferably have a molecular weight comprised in the range from 400 to 40 kDa. In one preferred variant of the invention the polyethylene glycol used has a molecular weight equal to or greater than 400 Da; values comprised from 10 to 40 kDa are especially preferred, more preferably from 20 to 40 kDa, even more preferably about 35 kDa.
- PEGs are considered rather non-toxic and non- immunogenic (Hermansky S.J et al., Food Chem Toxic., 1995, 33, 139-140; Final Report on the Safety Assessment of PEGs: J.A. C. T., 1993, 12, 429-457; Polyethylene glycol, 21 CFR 172.820, FDA).
- the maximum daily intake defined by the WHO is 10 mg/kg (Polyethylene glycols; Twenty-third report of the Joint FAO/WHO Expert Committee on Food Additives; World Health Organisation, Geneva; Technical Report Series 1980, 648, 17-18).
- Polyethylene glycol derivatives have advantages that are similar to traditional PEGs such as their aqueous solubility, physiological inactivity, low toxicity and stability under very different conditions. These derivatives include very different products and are characterized by the functional group substituting the hydroxyl, such as -NH2 (among the most reactive ones), phenol, aldehyde, isothiocyanate, -SH groups, etc. The following can be pointed out among the polyethylene glycol derivatives that can be used in the invention:
- PEG monomethyl ether monosuccinimidyl succinate ester PEG monomethyl ether monocarboxymethyl ether
- PEG adipate PEG distearate; PEG monostearate; PEG hydroxystearate; PEG dilaurate; PEG dioleate, PEG monooleate, PEG monoricinoleate; PEG coconut oil esters.
- Polyoxyethylene alkyl ethers PEG monomethyl ether or methoxy PEG (mPEG); PEG dimethyl ether.
- - PEG derivatives O,O'-Bis-(2-aminoethyl)polyethylene glycol (DAE-PEG 2000); O,O'-Bis-(2-aminopropyl)polypropylene glycol-polyethylene glycol-polypropylene glycol.
- the polyethylene glycol or derivative thereof is a polyethylene glycol.
- PEG polyethylene glycol 35000 (PEG35), polyethylene glycol 20000 (PEG20), polyethylene glycol 10000 (PEG10), and polyethylene glycol 6000 (PEG6).
- the polyethylene glycol is PEG35.
- PEGs are commercially available.
- the PEG is present on the surface of the nanoparticles comprising a zein matrix and a basic amino acid.
- the PEG is present as a coating.
- the nanoparticles may be totally or partially coated with PEG, preferably totally coated with PEG.
- PEG chains bind to the hydrophobic surface of the zein through multiple van der Waals interactions forming a layer all around the nanoparticle, thus, leading preferably to a total coating of the nanoparticles.
- the weight ratio of the polyethylene glycol or derivative thereof and zein is in the range of from 0.05: 1 to 1 :5, preferably from 0.05: 1 to 1 :1, preferably from 0.25: 1 to 1 : 1, more preferably from 0.4: 1 to 0.6: 1, even more preferably about 0.5: 1.
- the nanoparticles for use according to the invention are able to diffuse through the mucus layer, improving the absorption through the oral mucosa. This diffusion is particularly enhanced for PEGylated nanoparticles.
- the biological activity of the nanoparticles described herein is achieved in the absence of any pharmaceutically active ingredients used for the treatment of diabetes.
- the nanoparticles do not comprise any biologically active ingredient as previously defined.
- the nanoparticles do not comprise any antidiabetic drug.
- the nanoparticles do not comprise glibenclamide.
- the nanoparticles consist of the zein matrix, the basic amino acid and the polyethylene glycol or derivative thereof.
- the nanoparticle further comprises a biologically active ingredient, in particular an antidiabetic drug, more preferably an antidiabetic drug other than glibenclamide.
- biologically active ingredients and in particular the “antidiabetic drugs” are as previously defined.
- the nanoparticles do not comprise PVM/MA.
- PVM/MA is as previously defined.
- nanoparticles defined herein can be formulated in a composition.
- another aspect of the invention relates to a composition comprising at least one nanoparticle comprising a zein matrix, a basic amino acid and polyethylene glycol or a derivative thereof, and a pharmaceutically acceptable carrier for use in the treatment and/or prevention of a condition characterized by increased glucose levels and/or fat accumulation.
- composition comprising at least one nanoparticle comprising a zein matrix, a basic amino acid and polyethylene glycol or a derivative thereof, and a pharmaceutically acceptable excipient in the manufacture of a medicament for the treatment and/or prevention of a condition characterized by increased glucose levels and/or fat accumulation.
- composition comprising at least one nanoparticle comprising a zein matrix, a basic amino acid and polyethylene glycol or a derivative thereof, and a pharmaceutically acceptable excipient.
- compositions comprises a plurality of said nanoparticles.
- Said nanoparticles can be presented in the form of a suspension, preferably in an aqueous medium, or, alternatively, they can be presented in the form of a dry powder, for example as a lyophilizate together with a cryoprotective agent
- compositions are well known in the pharmaceutical art and are as previously defined.
- the pharmaceutical composition may be formulated in a solid (for example, tablets, capsules, coated tablets, granulates, suppositories, sterile crystalline or amorphous solids which can be reconstituted to provide liquid forms, etc.), liquid (for example suspension or dispersion of the nanoparticles, etc.) or semi solid (gels, pomades, creams and the like) pharmaceutical dosage form.
- a solid for example, tablets, capsules, coated tablets, granulates, suppositories, sterile crystalline or amorphous solids which can be reconstituted to provide liquid forms, etc.
- liquid for example suspension or dispersion of the nanoparticles, etc.
- semi solid gels, pomades, creams and the like
- pharmaceutical dosage form for example, tablets, capsules, coated tablets, granulates, suppositories, sterile crystalline or amorphous solids which can be reconstituted to provide liquid forms, etc.
- liquid for example suspension or dispersion of the
- said pharmaceutical composition is formulated as a pharmaceutical dosage form suitable for its administration by a route of access to mucosae.
- the pharmaceutical composition provided by this invention is orally administered; therefore the carrier or vehicle comprises one or more pharmaceutical excipients acceptable for the administration by oral route.
- Oral formulations are conventionally prepared by methods known by persons skilled in the art. A review of the different forms of administration of active ingredients, of the excipients to be used, and of the processes for manufacturing them can be found in the book “Tratado de Farmacia Galenica”, by C. Fault i Trillo, 10 Edition, 1993, Luzan 5, S.A. de Ediations.
- nanoparticles and compositions described herein are for the treatment and/or prevention of a condition characterized by increased glucose levels and/or fat accumulation, such as diabetes, obesity and metabolic syndrome
- the nanoparticles and compositions described above are for the treatment and/or prevention of diabetes, preferably for the treatment and/or prevention of type-2 diabetes or a prediabetes, more preferably for the treatment and/or prevention of type-2 diabetes.
- type-2 diabetes occurs when the body becomes resistant to insulin or there is not enough insulin produced. This type of diabetes is largely the result of excess body weight and physical inactivity. It is characterized by at least one of the following blood glucose levels: fasting plasma glucose level > 7.0 mmol/L (126 mg/dL) or plasma glucose > 11.1 mmol/L (200 mg/dL) two hours after a 75 g oral glucose load as in a glucose tolerance test.
- a prediabetic state or prediabetes is characterized by impaired fasting glucose levels and/or impaired glucose tolerance.
- Impaired fasting glucose levels are from 6.1 to 6.9 mmol/L (110 to 125 mg/dL).
- Impaired glucose tolerance is defined by a plasma glucose at or above 7.8 mmol/L (140 mg/dL), but not over 11.1 mmol/L (200 mg/dL), two hours after a 75 gram oral glucose load.
- the nanoparticles and compositions described above are for the treatment and/or prevention of obesity.
- obesity is a complex multifactorial disease defined by excessive adiposity that can impair health and it is also one of the key risk factors for many diseases such as coronary heart disease, hypertension and stroke, certain types of cancer, type 2 diabetes, etc.
- Body mass index (BMI) is a surrogate marker of adiposity calculated as weight (kg)/height 2 (m 2 ).
- the BMI categories for defining obesity vary by age and sex in infants, children and adolescents.
- obesity is defined by a BMI greater than or equal to 30 kg/m 2
- a BMI ranging from 25 to 29.99 kg/m 2 is also associated with increase disease risk and is referred to as pre-obesity or overweight.
- overweight is BMI-for-age greater than 1 standard deviation above the WHO Growth Reference median and obesity is greater than 2 standard deviations above the WHO Growth Reference median.
- overweight is weight-for-height greater than 2 standard deviations above WHO Child Growth Standards median whereas obesity is weight-for-height greater than 3 standard deviations above the WHO Child Growth Standards median.
- nanoparticles and compositions described above are for the treatment and/or prevention of metabolic syndrome.
- a person is defined as having metabolic syndrome if having central obesity (generally defined as waist circumference with ethnicity specific values but, if BMI is >30kg/m 2 , central obesity can be assumed and waist circumference does not need to be measured) plus any two of the following four factors: raised triglycerides > 150 mg/dL (1.7 mmol/L) or specific treatment for this lipid abnormality; reduced HDL cholesterol ⁇ 40 mg/dL (1.03 mmol/L) in males ⁇ 50 mg/dL (1.29 mmol/L) in females or specific treatment for this lipid abnormality; raised blood pressure systolic BP > 130 or diastolic BP > 85 mm Hg or treatment of previously diagnosed hypertension; raised fasting plasma glucose (FPG) > 100 mg/dL (5.6 mmol/L), or previously diagnosed type 2 diabetes (if FPG is above 5.6 mmol/L or 100 mg/dL, OGTT is strongly recommended but is not
- nanoparticles of the invention to be administered to a subject in need of treatment and/or prevention with the nanoparticles should be sufficient to trigger a beneficial therapeutic response in the patient over time.
- nanoparticles are administered to a patient in an amount sufficient to prevent, alleviate, reduce, cure or at least partially arrest symptoms and/or complications from the disease.
- An amount adequate to accomplish this is defined as a “therapeutically effective dose”.
- the dose can vary within a broad range, and will depend, for example on the frequency of administration and on the potency and duration of action, on the nature and severity of the disease and symptoms, and on the sex, age, weight, co-medication and individual responsiveness of the subject to be treated and on whether the therapy is acute or prophylactic.
- the dose of the nanoparticles to be administered to a subject may be comprised, for example, between approximately 0.1 and approximately 50 mg per kg of body weight, preferably, between 0.1 and 10 mg per kg of body weight.
- the subject to which the nanoparticles are administered is a human or animal; preferably subjects are mammals, more preferably humans.
- a further aspect of the present invention is directed to the non-therapeutic use of a nanoparticle comprising a zein matrix, a basic amino acid and polyethylene glycol or a derivative thereof for extending the lifespan of an organism.
- nanoparticles used in this aspect of the invention are as those described above.
- the nanoparticles used in this aspect of the invention are characterized by having an average particle size less than 1 pm, typically comprised between 1 and 999 nm, preferably between 10 and 900 nm, more preferably between 50 and 500 nm, more preferably between 100 and 450 nm, even more preferably between 140 and 400 nm, even more preferably between 150 and 300 nm, still more preferably from 150 to 250 nm.
- any zein can form the matrix of the nanoparticles used in this aspect of the invention; nevertheless, in a particular embodiment, said zein is a zein from corn, such as the zein supplied by Sigma-Aldrich (product number Z 3625).
- the basic amino acid present in the nanoparticles is as previously described.
- the basic amino acid of the nanoparticles used in this aspect of the invention is selected from the group consisting of lysine, arginine, histidine and mixtures thereof, preferably lysine.
- the weight ratio of zein to basic amino acid is in the range of from 0.01 : 1 to 50: 1, preferably from 0.5: 1 to 25: 1, more preferably from 1: 1 to 20:1, more preferably from 5:1 to 15:1, even more preferably from 6: 1 to 7: 1, still more preferably about 6.7: 1.
- nanoparticles used in this aspect of the invention comprise a polyethylene glycol polymer or derivative thereof as described above.
- the polyethylene glycols used preferably have a molecular weight comprised in the range from 400 to 40 kDa. In one preferred variant of the invention the polyethylene glycol used has a molecular weight equal to or greater than 400 Da; values comprised from 10 to 40 kDa are especially preferred, more preferably from 20 to 40 kDa, even more preferably about 35 kDa.
- the polyethylene glycol or derivative thereof is a polyethylene glycol.
- PEG polyethylene glycol 35000 (PEG35), polyethylene glycol 20000 (PEG20), polyethylene glycol 10000 (PEG10), and polyethylene glycol 6000 (PEG6).
- the polyethylene glycol is PEG35.
- PEGs are commercially available.
- the PEG is present on the surface of the nanoparticles comprising a zein matrix and a basic amino acid.
- the PEG is present as a coating.
- the nanoparticles may be totally or partially coated with PEG, preferably totally coated with PEG.
- PEG chains bind to the hydrophobic surface of the zein through multiple van der Waals interactions forming a layer all around the nanoparticle, thus, leading preferably to a total coating of the nanoparticles.
- the weight ratio of the polyethylene glycol or derivative thereof and zein is in the range of from 0.05: 1 to 1 :5, preferably from 0.05: 1 to 1 :1, preferably from 0.25: 1 to 1 : 1, more preferably from 0.4: 1 to 0.6: 1, even more preferably about 0.5: 1.
- the nanoparticles used in this aspect of the invention do not comprise any biologically active ingredient, as defined above. More particularly, the nanoparticles used in this aspect consist of the zein matrix, the basic amino acid and the polyethylene glycol or derivative thereof.
- the nanoparticles used in this aspect of the invention comprise a biologically active ingredient.
- the nanoparticles do not comprise PVM/MA.
- PVM/MA is as previously defined.
- the nanoparticles used in this aspect of the invention can be formulated in a composition.
- another aspect of the invention relates to the non-therapeutic use of a composition comprising at least one nanoparticle as defined herein, i.e. comprising a zein matrix, a basic amino acid and polyethylene glycol or a derivative thereof, and an excipient acceptable in food or nutraceutics, for extending the lifespan of an organism.
- Said composition comprises a plurality of said nanoparticles.
- said nanoparticles can be presented in the form of a suspension, preferably in an aqueous medium, or, alternatively, they can be presented in the form of a dry powder, for example as a lyophilizate together with a cryoprotective agent.
- compositions for use according to this aspect are a food, or nutraceutical product, as previously defined.
- the product is a food, a feed or a food for special medical purposes comprising the nanoparticles described herein and a food acceptable vehicle or carrier.
- the product is nutraceutical product as previolsy defined comprising the nanoparticles described herein and a nutraceutical acceptable vehicle or carrier.
- excipient in food and nutraceutics have been described above.
- the choice of excipient can be selected with regard to the type of composition or product, the intended route of administration and standard practice.
- composition of the invention may be formulated as a liquid, semi-solid or solid form.
- said composition is formulated as a dosage form suitable for its administration by a route of access to mucosae.
- the composition provided by this invention is orally administered; therefore the carrier or vehicle comprises one or more excipients acceptable for the administration by oral route.
- the organisms to which the nanoparticles are administered are preferably mammals, more preferably humans.
- the term “extending the lifespan of an organism” is as previously defined.
- the increase in the lifespan is of at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70% or at least 80% with respect to the projected lifespan in the absence of the nanoparticles.
- the increase in the lifespan is from 10% to 50%.
- said increase in the lifespan is characterized by a reduction of the glucose levels, fat accumulation and/or intracellular ROS levels in the organism to which the nanoparticles are administered.
- the zein nanoparticles for use according to the present invention may be prepared using a desolvation method, such as that described by Penalva et al. [J. Agric. Food Chem., 2015, 63(23), 5603-5611] or as that described in WO 2012/007628 Al as “process [1]” (which is incorporated herein by reference).
- Said method comprises: a) preparing a hydroalcoholic solution containing a zein and a basic amino acid; and b) adding water to the solution of step a).
- the hydroalcoholic solution used in step a) contains water and an alcohol, typically ethanol; in a particular embodiment, said hydroalcoholic solution comprises between 25% and 75% (w/v) of alcohol, preferably between 30% and 60%, more preferably about 55%.
- the amount of zein present in the hydroalcoholic solution formed in step a) can vary within a wide range; nevertheless, in a particular embodiment, the amount of zein contained in said hydroalcoholic solution is comprised between 0.1% and 20% (w/v, expressed as weight in mg and volume in mL), preferably between 5% and 15%, more preferably about 10%.
- the amount of basic amino acid present in the hydroalcoholic solution formed in step a) can vary within a wide range. Generally, said amount is usually expressed according to the amount of zein to be dissolved. Said weight ratio of zein to basic amino acid is preferably in the range of from 0.01 : 1 to 50: 1, preferably from 0.5: 1 to 25: 1, more preferably from 1: 1 to 20:1, more preferably from 5: 1 to 15: 1, even more preferably from 6: 1 to 7: 1, still more preferably about 6.7: 1.
- step b) of process water is added in an amount sufficient for the formation of the nanoparticles for use according to the invention.
- amount of water to be added can vary within a wide range, in a particular embodiment, water is added in an amount sufficient for the final proportion of alcohol in the medium to be comprised between 10% and 60% (w/v), preferably between 15% and 30%, more preferably between 20% and 25%.
- the nanoparticles are isolated by removal of the alcohol by conventional means, such as evaporation at reduced pressure to provide a suspension of the nanoparticles.
- This suspension may be concentrated and purified by tangential filtration.
- the resulting suspension may be dried by conventional means such as spray-drying, in particular using the experimental conditions described in the examples.
- Drug loaded nanoparticles may also be prepared as described above but further adding the antidiabetic drug to the solution of step a). These nanoparticles may also be prepared following the procedures described in WO 2012/007628 Al as “process [2]” and “process [3]” (which are incorporated herein by reference).
- PEGylated nanoparticles may be prepared by simple incubation of the nanoparticles obtained as described above with the corresponding polyethylene glycol or derivative thereof.
- a solution of polyethylene glycol or a derivative thereof in water is prepared, preferably to a concentration of polyethylene glycol or derivative thereof in said solution between 50 and 200 mg/mL, more preferably between 50 and 150 mg/mL, still more preferably about 100 mg/mL.
- Said solution is contacted with a suspension of the nanoparticles in water previously obtained.
- the amount of solution of polyethylene glycol or derivative thereof contacted with the suspension of nanoparticles can vary within a wide range. Said amount depends on the target weight ratio of polyethylene glycol or derivative thereof to zein. Said weight ratio of the polyethylene glycol or derivative thereof and zein is in the range of from 0.05: 1 to 1 :5, preferably from 0.05: 1 to 1 :1, preferably from 0.25: 1 to 1 :1, more preferably from 0.4:1 to 0.6: 1, even more preferably about 0.5: 1.
- the contacting is preferably carried out by mixing at a temperature in the range of 15 to 30 °C, preferably of 20 to 25 °C, for a period of time of about 15 min to 1 h, preferably for about 30 min.
- the resulting suspension of PEGylated nanoparticles may be concentrated and purified by tangential filtration.
- the resulting suspension may be dried by conventional means such as spray-drying, in particular using the experimental conditions described in the examples.
- compositions for use according to the invention may be prepared by mixing the ingredients contained in said compositions.
- Embodiment 1 A nanoparticle comprising a zein matrix and a basic amino acid for use in the treatment and/or prevention of diabetes, wherein the nanoparticle does not comprise glibenclamide.
- Embodiment 2 The nanoparticle for use according to embodiment 1, wherein the basic amino acid is selected from the group consisting of lysine, arginine, histidine and mixtures thereof.
- Embodiment 3 The nanoparticle for use according to embodiment 2, wherein the basic amino acid is lysine.
- Embodiment 4 The nanoparticle for use according to any one of the preceding embodiments, wherein the weight ratio of zein to basic amino acid is in the range of from 0.01 : 1 to 50: 1, preferably from 0.5: 1 to 25: 1, more preferably from 1 : 1 to 20: 1, more preferably from 5: 1 to 15: 1, even more preferably from 6: 1 to 7: 1.
- Embodiment 5 The nanoparticle for use according to any one of the preceding embodiments, wherein its average size is in the range of from 100 to 450 nm, preferably from 150 to 250 nm.
- Embodiment 6 The nanoparticle for use according to any one of the preceding embodiments, which further comprises a polyethylene glycol or derivative thereof.
- Embodiment 7 The nanoparticle for use according to embodiments 6, wherein the polyethylene glycol or derivative thereof has a molecular weight in the range of from 400 Da to 40 kDa, preferably from 10 to 40 kDa, more preferably from 20 to 40 kDa, even more preferably about 35 kDa.
- Embodiment 8 The nanoparticle for use according to embodiment 6 or 7, wherein the polyethylene glycol is polyethylene glycol 35000 (PEG35).
- Embodiment 9 The nanoparticle for use according to any one of embodiments 6 to 8, wherein the weight ratio of the polyethylene glycol or derivative thereof and zein is in the range of from 0.05: 1 to 1 :5, preferably from 0.05: 1 to 1 : 1, preferably from 0.25: 1 to 1 : 1, more preferably from 0.4: 1 to 0.6: 1, even more preferably about 0.5: 1.
- Embodiment 10 The nanoparticle for use according to any one of the preceding embodiments, wherein the nanoparticle does not comprise any antidiabetic drug.
- Embodiment 11 The nanoparticle for use according to any one of embodiments 1 to 9, wherein the nanoparticle further comprises an antidiabetic drug other than glibenclamide.
- Embodiment 12 A composition comprising at least one nanoparticle as defined in any one of the preceding embodiments and a pharmaceutically acceptable excipient for use in the treatment and/or prevention of diabetes.
- Embodiment 13 The nanoparticle for use according to any one of embodiments 1 to 11 or the composition for use according to embodiments 12, wherein diabetes is type-2 diabetes or prediabetes.
- Embodiment 14 Non-therapeutic use of a nanoparticle as defined in any one of embodiments 1 to 11 for extending the lifespan of an organism.
- Embodiment 15 Non-therapeutic use of a composition comprising at least a nanoparticle as defined in any one of embodiments 1 to 11 and a carrier acceptable in food or nutraceutics, for extending the lifespan of an organism.
- Zein nanoparticles were prepared by a desolvation method as described previously [R. Penalva et al., J. Agric. Food Chem., 2015, 63(23), 5603-5611], with minor modifications, followed by an ultrafiltration purification step and subsequent spraydrying. Briefly, 200 mg zein and 30 mg lysine were dissolved in 20 mL ethanol 55% with magnetic stirring for 10 minutes at room temperature. Nanoparticles were formed by the addition of 20 mL purified water. The ethanol was removed using a rotatory evaporator under reduced pressure (Buchi Rotavapor R-144; Buchi, Postfach, Switzerland) and the resulting suspension was concentrated and purified by tangential filtration.
- Lumogen® red-loaded nanoparticles 2.6 mL of a Lumogen® red solution at 0.4 mg/mL was added to the solution of zein and lysine, prior to the formation of the nanoparticles. After incubation, the nanoparticles were formed, purified and dried as described above.
- the coating of nanoparticles with PEG35 was performed by simple incubation between the just formed nanoparticles (before the purification step) and PEG 35,000 at different PEG-to-zein ratios.
- a stock solution of PEG 35,000 was prepared by dissolving the polymer in water to a final concentration of 100 mg/mL. Then, different volumes of this stock solution were added to the suspension of freshly nanoparticles. The mixture was maintained under magnetic agitation for 30 minutes at room temperature. After this time, nanoparticles were concentrated and purified by tangential filtration and drying as descried above.
- Fluorescently-labelled nanoparticles were prepared by encapsulating Lumogen® red as described in section 2.1.
- Particle size and polydispersity index (PDI) were measured by photon correlation spectroscopy (PCS) after dispersion in ultrapure water (1/10), at 25 °C, by dynamic light scattering (angle of 90°).
- Zeta-potential (Q was determined by electrophoretic laser Doppler anemometry after the dispersion of nanoparticles in purified water as follows: 200 pL of the samples were diluted in 2 mL of a 0.1 rnM KC1 solution adjusted to pH 7.4. All the already mentioned measurements were performed using a Zetasizer analyzer system (Brookhaven Instruments Corporation, New York, USA). The shape and surface morphology of the nanoparticles was studied by scanning electron microscopy (SEM) after resuspension in water.
- SEM scanning electron microscopy
- the amount of zein forming nanoparticles was estimated by two different techniques.
- One technique consisted on the quantification of the zein present in the elute obtained from the purification/concentration step.
- the amount of zein present in the elute was quantified spectrophotometrically by measuring the absorbance at 300 nm wavelength.
- Two standard curves were added to the procedure, one containing increasing concentrations of pure zein dissolved in ethanol 70%, and, another one containing the same dilutions but in the presence of lysine at the same proportion as the one used to formulate the nanoparticles (15%, w/w).
- the other technique consisted on a capillary electrophoresis quantification of the nanoparticles after centrifugation, as purification step.
- the nanoparticle formulation was dispersed in water and centrifuged at 15,000 x g for 20 min. Supernatants were discarded and the pellets were digested with ethanol 75%. Then, the amount of protein was quantified by capillary electrophoresis-Experion system (Bio-Rad Laboratories, Hercules, CA). Samples were analyzed under reducing and non-reducing conditions according to the manufacturer’s instructions (Experion Pro260 Analysis kit; Bio-Rad Laboratories). A solution of molecular mass protein standards (ladder) included in the kit was used to determinate the content of protein in a sample. For data analysis, Experion software version 3.10 (BioRad Laboratories) was used. The amount of protein forming nanoparticles in the formulation was estimated as the ratio between the amount of the protein quantified in the pellet of the centrifuged samples and the total amount of protein used for the preparation of nanoparticles and expressed in percentage.
- the surface hydrophobicity of the formulations was evaluated using the Rose Bengal test [S. Doktorovova et al., Eur. J. Pharm. Sci., 2012, 45(5), 606-612] with some minor modifications. Briefly, 500 pL of nanoparticle suspensions (from 0.03 to 3 mg/mL) was mixed with 1 mL of a Rose Bengal aqueous solution (100 pg/mL). All samples were incubated under constant shaking at 1500 rpm, for 30 min at 25 °C (Labnet VorTemp 56 EVC, Labnet International, Inc.). Afterwards, the samples were centrifuged at 13,500 x g for 30 min (centrifuge MIKRO 220, Hettich, Germany).
- the amount of Rose Bengal in the supernatants was calculated by measuring the absorbance at 548 nm, using a microplate reader (BioTek PowerWave XS, USA). Further, the total surface area (TSA) of each sample was plotted against the partitioning quotient (PQ) calculated in accordance with the following equation:
- the slope of the line of the chart represents the hydrophobicity of the formulation. The higher the slope, the higher the hydrophobicity.
- MPT Multiple Particle Tracking
- K is the Boltzmann constant
- T absolute temperature
- q water viscosity
- r is the mean radius of nanoparticles.
- the diffusion of all the formulations was expressed as the ratio (%) between their Deff and their D Q (diffusions in mucus and in water, respectively). This ratio provides a measure of the relative diffusion of the nanoparticles in mucus when considering their Brownian motion in water.
- Caernoharbditis elegans (C. elegans) was maintained and cultured as described previously [S. Brenner, Genetics, 1974, 77, 71-94], Wild-type N2 Bristol strain was obtained from the Caenorhabditis Genetics Center (CGC, University of Minnesota, MN), and were cultured at 20 °C on NGM (Nematode Growth Medium) agar with Escherichia coll OP50 as normal nematode diet.
- age-synchronized worms were obtained by hypochlorite treatment, a condition in which only eggs can survive, and eggs were let hatch overnight in M9 buffer solution [J. GrieBinger et al., Eur. J. Pharm. Biopharm., 2015, 96, 464-476],
- Lumogen® red-loaded nanoparticles were supplemented to the growth medium of C. elegans. After the drying of the supplemented NGM plates, 50 pL of a culture of OP50 were added over the solid- NGM-containing plates and let dry in darkness. Finally, about 500 adult worms were added to each well and incubated at 20 °C for 2 hours. After incubation time, worms were collected and fixed in glass slides with 2% agarose supplemented with sodium azide (1%) to kill the worms. Then, the already fixed worms were observed with a Nikon eclipse 80i epi-fluorescent microscope using the rhodamine filter to see the Lumogen®-loaded nanoparticles. The contrast image of the whole worms was obtained with the DAPI filter since C. elegans shows autofluorescence in that range.
- the fat content quantification in the nematodes was performed by the fixative-based the Nile red method [E. C. Pino et al., J. Vis. Exp., 2013, 73, e50180; and D. Navarro-Herrera et al., Food Fund., 2018, 9(3), 1621-1637], Briefly, L4 worms grown under the different conditions were harvested and washed with 0.01% of Triton X-100 in phosphate-buffered saline (PBST) and fixed in 40% isopropanol. Staining was performed by adding Nile Red solution (3 pg/mL) and incubating in the dark.
- Nile Red solution 3 pg/mL
- the worms were washed in PBST and mounted on a 2% agarose pad for microscopy visualization.
- Fluorescent images of Nile Red stained worms were captured at 80* magnification on a Nikon SMZ18 stereomicroscope (Nikon Instruments Inc., Tokyo, Japan) equipped with an epifluorescence system and a DS-FI1C refrigerated color digital camera.
- the images were taken under a GFP filter (Ex 480-500, DM 505; BA 535-550). Image analysis was performed using ImageJ program.
- the lifespan assay was monitored at 20 °C under high glucose conditions (HG) [J. Apfeld and C. Kenyon, Nature, 1999, 402(6763), 804-809], NGM plates containing 40 mM of FUdR were used to prevent the growth of new worms.
- Nematodes were regarded as dead if they do not move after repeated mechanical stimulus. All experiments were repeated at least three times and -100 worms were used for each experiment.
- Intracellular ROS in C. elegans was quantified using the molecular probe H2DCF-DA as described previously [Z. Wang et al., Exp. Gerontol., 2016, 82, 139-149],
- H2DCF-DA molecular probe for ROS detection
- 60 worms at certain ages were harvested for each treatment and washed with PBST.
- the worms were resuspended in M9 buffer.
- fresh H2DCF-DA was added to a final concentration of 50 pM.
- Age-synchronous L4 larvae were cultured in the presence of FUdR (100 pM) and treated with or without 5 mg/L NP for 10 days for intestinal lipofuscin accumulation test.
- Ten- day old wild-type nematodes were collected on a microscope slide with 2% agar pad and anesthetized with sodium azide (1%).
- the autofluorescence of lipofuscin was captured by a Nikon eclipse 80i epifluorescent microscope. The experiment was performed in triplicate. The relative fluorescence intensity was quantified using ImageJ software to determine the lipofuscin levels.
- Glucose levels in C. elegans were quantified as described [M. Mendler et al., Diabetologia, 2014, 55(2), 393-401], with some modifications. Approximately 1000 worms for each treatment were harvested and washed using PBST buffer. Pelleted worms were then lysed by beat beating in homogenization buffer (PBST, 10 mmol/L NP40) containing a protease inhibitor cocktail (Complete; Roche Diagnostics, Risch-Rotkreutz, Switzerland). Nematodes were homogenised using a mini-Beadb eater (Biospec Products, Bartlesville, OK) at speed 10 for 2 x 2 min.
- PBST homogenization buffer
- NP40 homogenization buffer
- Nematodes were homogenised using a mini-Beadb eater (Biospec Products, Bartlesville, OK) at speed 10 for 2 x 2 min.
- worm homogenates were centrifuged at 16,000 x g for 5 min, and the supernatant fractions were assays for protein concentration (BCA Protein Assay Kit; Thermo Fisher Scientific, Waltham, MA) and glucose concentration (Accu-Check Aviva; Roche Diagnostics, Risch-Rotkreutz, Switzerland).
- mice Male Wistar rats weighing 180-220 g were purchased from Envigo (Indianapolis, USA). Animals were housed under controlled temperature (23 ⁇ 2 °C) with 12-hour light/dark cycles and with free access to normal chow and water. All experiments were performed after a minimum acclimation period or 7 days. Prior to any procedure, animals were fasted overnight. During the procedures, animals were kept fasted but with free access to water. All the procedures were performed following a protocol previously approved by the “Ethical and Biosafety Committee for Research on Animals” at the University of Navarra in line with the European legislation on animal experiments.
- mice were divided in different groups of 6 animals each.
- Each group of animals received orally one of the following treatments: (i) dispersion of free zein in water (50 mg/kg), (ii) zein nanoparticles dispersed in water (NP; 50 mg/kg), (iii) PEG-coated zein nanoparticles prepared at a polymer-to-zein ratio of 0.5 (PEG-NP; 50 mg/kg). All these formulations were dispersed in 1 mL water prior administration to animals through oral gavage, using a stainless-steel cannula. As controls, one group of animals received orally 1 mL water.
- Rat insulin was quantified using ELISA kit (EZRML13K; Merck; Darmstadt, Germany) and GLP-1 was quantified using an ELISA kit (YK160 GLP-1 EIA Kit; Yanaihara Institute Inc; Awakura, Japan).
- the ipGTT was performed to evaluate the change in the glycemic control of rats receiving different treatments when facing an intraperitoneal injection of glucose (2 g/kg).
- Treatments were administered by oral gavage 2 hours before the intraperitoneal injection of glucose. Blood glucose levels were measured at several times, before and after the intraperitoneal injection of glucose: -120 minutes (just before oral administration of nanoparticles), To (time of the intraperitoneal injection of glucose) and 15, 30, 60 and 120 minutes after the glucose overload. Blood samples (50 pL) were collected from the tail vein and the glycemia was measured using a glucometer (Accu-Check® Aviva glucometer; Roche Diagnostics, Basel, Switzerland).
- SAMP8 mice were used due to their reduced lifespan, associated with an accelerated age-related degeneration [V. Karuppagounder et al., Ageing Res. Rev., 2017, 35, 291-296; E. M. Rhea and W. A. Banks, Exp. Gerontol., 2017, 94, 64-68; J. F. Flood and J. E. Morley, Neurosci. Biobehav. Rev., 1997, 22(1), 1-20; and T.
- mice 7-month-old mice were chosen because this strain develops a normal growth until the age of around 6 months, when they start developing the typical age-related characteristics and pathologies [K. Yamamoto et al., Nutrition, 2016, 32(1), 122-128], Moreover, only males were used because it has been reported that female mice show less cognitive degeneration [J. E. Morley et al., Biochim. Biophys. Acta - Mol. Basis Dis., 2012, 7522(5), 650-656], The formulation was prepared as described previously and resuspended in water before administration. All the animals were administered through oral gavage, using a stainless-steel cannula.
- mice were allowed to get older and die naturally. Moribund animals were immediately euthanized by cervical dislocation. Animals were considered as moribund if they fail to eat or drink, did not respond to touch stimuli, became completely blind (due to the degeneration of typical periophthalmic lesions [Y. Nomura and Y. Okuma, Neurobiol. Aging, 1999, 20(2), 111-115]) or developed tumors. The weight of the mice was followed up during the experiment.
- Wistar male rats were purchased from Envigo (Envigo Research Models and Services, Indianapolis, IN). The experiments began after acclimating the animals for at least 2 weeks under constant conditions of temperature (22 ⁇ 1 °C), humidity (50% ⁇ 10%), and artificial dark/light cycles (12 h each) with free access to standard control diet (2014, Teklad, Global 14% Protein Rodent Maintenance Diet) and water. All the procedures were performed following a protocol previously approved by the “Ethical and Biosafety Committee for Research on Animals” at the University of Navarra in line with the European legislation on animal experiments (protocol 016-21).
- HFS-NP HFS-NP
- the formulation was prepared as described previously and dispersed in 1 mL water prior administration to animals through oral gavage, using a stainless-steel cannula.
- SC and HFS groups received orally 1 mL water. Prior to procedure, animals were fasted for 8 hours and, after administration, the water and food were supplied ad libitum. Body weight was measured weekly.
- Total body fat and lean mass were determined for each animal at week 5 of the treatment period by quantitative magnetic resonance spectroscopy using the EchoMRITM system (Echo Medical Systems, Houston, TX). The scans were achieved by placing live animals into a thin-walled plastic cylinder (3 mm thick, 6.8 cm internal diameter), and a cylindrical plastic insert to limit the rat movement. While in the cylinder, the animals were briefly subjected to a low-intensity electromagnetic field (0.05 Tesla) for 2 min (Nixon et al., Obesity (Silver Spring). 2010; 18(8): 1652-9). Measures of body fat and lean mass proportions were performed in triplicate and were calculated relative to total body weight, together with the relation between fat and lean mass proportions at the end of the study.
- EchoMRITM Echo Magnetic Imaging
- Triacylglycerides TAG
- total cholesterol total cholesterol
- HDL high-density lipoprotein
- concentrations of monocyte chemotactic protein- 1 (MCP-1) in plasma were quantified using a specific ELISA kit (Thermo Scientific and Life Technologies).
- Atherogenic index of plasma AIP was calculated as the quotient between TAG and HDL, and expressed as log (Bahadoran et al., Int J Food Sci Nutr. 2012; 63(7):767-71).
- the main physico-chemical characteristics of empty nanoparticles coated at different PEG-to-zein ratios are shown in Table 1.
- the coating with PEG did not significantly modify the size and zeta potential of the formulations, compared to naked nanoparticles (NP).
- All the formulations showed an average size of about 210 nm with poly dispersity index (PDI) values always lower than 0.1.
- the zeta potential of the formulations was always negative, with values around -50 mV.
- the yield of the process expressed as the amount of zein transformed into nanoparticles, this parameter was close to 80%, when quantified spectrophotometrically or by capillary electrophoresis.
- Figure 3 shows a comparison of the normalized values of diffusion in mucus (taking the capability of NP to diffuse in mucus as 1). Overall, significant differences were found for the different formulations tested. As expected, there is a direct relationship between the PEG-to-zein ratio of the coating of the nanoparticles and their capability to diffuse through the mucus. The higher PEG-to-zein ratio, the higher mucus diffusion. Thus, for PEG-coated nanoparticles at a ratio of 0.75 (NP75), the diffusion coefficient in mucus was 9 times higher than for uncoated nanoparticles (NP). However, no significant differences were found between nanoparticles coated at ratios of 0.25, 0.5 and 0.75.
- Fluorescence micrographs of worms cultured in normal conditions or cultured in medium supplemented with Lumogen-loaded nanoparticles evidence the intake of nanoparticles by C. elegans. Fluorescently labelled nanoparticles can be observed along the gastrointestinal tract of the worm 2 hours after culture.
- the maximum lifespan was also lengthened by NP from 24.98 to 34.87 days.
- the mean and median lifespan of C. elegans treated with NP was 43% and 38% higher than for control worms.
- the maximum lifespan value for the animals treated with nanoparticles was 39.6% higher than for the control nematodes.
- lipofuscin (as a model physiological marker of aging) was measured.
- Lipofuscin is an endogenous autofluore scent marker of cellular damage during aging in many organisms, including C. elegans [Z. Pincus and F. J. Slack, Dev. Dyn., 2010, 239(5), 1306-1314; and N. Papaevgeniou et al., Free Radic. Biol.
- Daf-16 and SKN-1 are two classical transcription factors that are closely related to oxidative stress and longevity [X. Sun, W.-D. Chen, and Y.-D. Wang, Front. Pharmacol., 2017, 8, 548; and T. K. Blackwell et al., Free Radic. Biol. Med., 2015, SS(Pt B), 290-301],
- synchronized wild-type LI worms were treated with or without NP for 6 days.
- the qRT-PCR results showed a NP upregulation of transcriptional expression levels of daf-16 and skn-1, by 1.8 and 2.1-fold respectively, compared with their expression levels in control worms (Figure 7).
- Fluorescence micrographs of duodenum slices obtained 2 hours post-administration of different Lumogen-loaded formulations to animals showed that both bare and PEG- coated nanoparticles at a PEG-to-zein ratio of 0.05 displayed a localization that seemed to be restricted to the mucus layer that covers the epithelium, without presence between intestinal villi. Nevertheless, PEG-coated nanoparticles at higher PEG-to-zein ratios (0.25 and 0.5) were clearly seen in close contact with the intestinal epithelium, occupying the inter-villi spaces and even reaching the intestinal crypts.
- Figure 8 shows the blood glucose levels of healthy male Wistar rats treated with the different treatments.
- the glycemia of rats treated with free zein at a dose of 50 mg/kg showed no differences compared to the control rats, which received water.
- NP induced a 25% reduction in the glycemia 3 hours after the oral administration, reduction that was maintained for at least 6 hours.
- the glycemic decrease was found to be 28% 3 hours after the oral administration, being slightly greater than those treated with NP.
- the decrease increased to a 32% 6 hours after the administration, being significantly greater than the reduction induced by NP.
- Figure 9 shows the concentration in blood of the different hormones after the administration of the treatments with the nanoparticles of the invention and the control group, normalizing the values to the initial concentrations.
- Figure 9A displays the changes in the insulin concentration of the rats treated with the different treatments. A reduction in the insulinemic values can be seen in the control animals, which received only water. 1.5 hours after the administration, control animals showed a 52% reduction in the insulinemia when compared to the initial values. This decrease reached the value of 96% 3 hours after the beginning of the experiment and 91% for 6 hours after.
- NP50 showed lesser effect than NP in stimulating the insulin release in rats, although no statistical differences were found.
- the changes in the insulinemia of NP50-treated animals was a 32% and 28% decrease 1.5 and 3 hours after the administration, followed by a 67% increase 6 hours post-administration.
- Intraperitoneal Glucose Tolerance Test in healthy rats The response to a glucose overload in rats was evaluated through an intraperitoneal glucose tolerance test. Two hours after the oral administration of treatments, rats were injected with a glucose solution equal to 2 g/kg. Figure 10A shows the changes in the glycemia of rats during the 2 hours after the challenge with glucose injection. All the treatments significantly reduced the glycemic increase 15 minutes after the challenge, compared to the controls. Only the group treated with NP50 showed a significant reduction in the glucose rise 30 minutes after the glucose injection, leading to a very significant decrease compared to control and free zein groups. From this point on, no differences were found among all treatments.
- zein nanoparticles dispersed in water
- the survival curves are represented in Figure 11.
- the NP -treated group displays a right shift of the curve, which represents an increment in the lifespan of the mice (p ⁇ 0.05).
- This group (NP) shows also a delay in the age of the first death, median (with a 32% increase in the median lifespan expectancy) and maximum lifespan (the maximum lifespan of mice increased by 40% when treated with NP) (Table 1).
- AUC area under the curve
- Table 1 Summary of the effect of bare zein nanoparticles (NP) administration on the median, mean and maximum survival for SAMP8 mice.
- Figure 12 represents the modifications in the body composition of obese rats (expressed as the fat content relative to the body weight and as the fat mass-to-lean mass ratio) when fed daily with zein nanoparticles during 6 weeks. Interestingly, after 6 weeks, supplementation of HFS-fed animals with zein nanoparticles induced a significant decrease of the fat content (about 24%; p ⁇ 0.01), compared with control animals (HFS). The weight of adipose tissues is presented in Figure 13.
- HFS-fed animals clearly decreased the mass of retroperioneal (20%; p ⁇ 0.01), epididymal (19%; p ⁇ 0.01), subcutaneous (19%; p ⁇ 0.001) and visceral fat (18%; p ⁇ 0.05), when compared with control animals (HFS group).
- Figure 14 compiles the biochemical parameters of lipid profile in animals at the end of the study. Serum HDL-Cholesterol and total cholesterol were similar for animals included in the HFS and the HFS-NP groups. On the contrary, the triglycerides (TAG) concentration were significantly lower in HFS-fed animals receiving a daily dose of zein nanoparticles (42% reduction) with respect with control HFS animals (p ⁇ 0.001). Interestingly, these serum levels of TAG in the HFS-NP animals were similar to that quantified in the SC group.
- TAG triglycerides
- Figure 16 shows the levels of triglycerides in the liver of animals.
- a portion of the liver was analyzed.
- supplementation of HFS-fed animals with zein nanoparticles significantly attenuated the typical lipid steatosis of these animals (about 30% reduction in the levels of triglycerides; p ⁇ 0.01).
- histopathological studies revealed that the HFS diet led to an enlargement of the hepatocytes and an increase in the number of lipid droplets in the liver compared to the SD group.
- photomicrographs of hematoxylin-and-eosin-stained sections from HFS-fed animals supplemented with zein nanoparticles (revealed liver structures similar to those of animals fed with the standard diet (SC group).
- zein nanoparticles improves glucose tolerance in healthy rats.
- the results show that in a fasted state, zein nanoparticles induced an important decrease in the glucose blood levels (between 25-30%, compared with basal levels, 3 hours post-administration), while control animals did not show any change in the glycemia.
- Another of the objectives of the present study was to investigate the effect induced by zein nanoparticles on lifespan and longevity of a C. elegans model and a mouse model with accelerated aging (SAMP8).
- the results showed that the treatment with zein nanoparticles prolonged of lifespan in both nematodes (about 35%) and aged mice (about 30%) compared to their respective controls.
- NP treatment mitigated the negative effect of high-glucose conditions lead to an increase of the mean and maximum lifespan of nematodes.
- This lifespan extension may be related to a protective effect against the damage induced by the ROS derived from high-glucose conditions.
- An important factor for aging is the accumulation of oxidative stress caused by an increase in intracellular ROS levels.
- mice may be attributed, at least in part, to the anti-aging mechanisms described above for C. elegans.
- the lifespan-extension in the mice might also be related to an improvement or restoration of some metabolic functions. Aging is associated with a lot of metabolic changes that reduce the lifespan, including a decline in the modulation of metabolic function and insulin sensitivity [T. Finkel, Nat. Med., 2015, 27(12), 1416-1423], Recently, SAMP8 mice have been proposed as a model to study age-related metabolic complications.
- mice The short-life of these mice is related to the development of adipocyte hypertrophy and ectopic lipid accumulation in the liver that increase insulin resistance and lead to hyperglycemia and impaired glucose tolerance at 40-week-old [H. W. Liu et al., Exp. Gerontol., 2017, 99(1), 61-68], We found that supplementation with zein nanoparticles delays the age of the first death and increases the median and the maximum lifespan of the mice. These results suggest that NP-treatment may be mitigating these age- related metabolic disorders and, consequently, improving lifespan.
Abstract
L'invention concerne l'utilisation de nanoparticules comprenant une matrice de zéine et un acide aminé basique, et des compositions comprenant lesdites nanoparticules, dans le traitement et/ou la prévention de pathologies caractérisées par des taux accrus de glucose et/ou une accumulation de graisses, en particulier l'utilisation médicale dans le traitement et/ou la prévention du diabète et l'utilisation non thérapeutique pour prolonger la durée de vie d'un organisme.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP20383153 | 2020-12-23 | ||
PCT/EP2021/087031 WO2022136393A1 (fr) | 2020-12-23 | 2021-12-21 | Nanoparticules de zéine destinées à être utilisées dans des pathologies avec hyperglycémie |
Publications (1)
Publication Number | Publication Date |
---|---|
EP4267114A1 true EP4267114A1 (fr) | 2023-11-01 |
Family
ID=74194485
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP21840943.1A Pending EP4267114A1 (fr) | 2020-12-23 | 2021-12-21 | Nanoparticules de zéine destinées à être utilisées dans des pathologies avec hyperglycémie |
Country Status (2)
Country | Link |
---|---|
EP (1) | EP4267114A1 (fr) |
WO (1) | WO2022136393A1 (fr) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115624612A (zh) * | 2022-10-14 | 2023-01-20 | 广州顺泰生物医药科技有限公司 | 一种减肥降脂药物及其制备方法 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2571874B2 (ja) * | 1989-11-06 | 1997-01-16 | アルカーメス コントロールド セラピューティクス,インコーポレイテッド | タンパク質マイクロスフェア組成物 |
EP2214747A2 (fr) | 2007-11-20 | 2010-08-11 | Cook Incorporated | Administration régulée de médicament à l'aide d'une couche de zéine modifiée par de l'acide lévulinique |
WO2012007628A1 (fr) | 2010-07-16 | 2012-01-19 | Instituto Científico Y Tecnológico De Navarra, S.A. | Nanoparticules pour encapsulation de composés, obtention et utilisations de celles-ci |
EP3581176A1 (fr) * | 2018-06-12 | 2019-12-18 | Universidad de Navarra | Nanoparticules de zéine de type noyau-enveloppe pour encapsulation de composés, leur procédé de préparation et leurs utilisations |
-
2021
- 2021-12-21 EP EP21840943.1A patent/EP4267114A1/fr active Pending
- 2021-12-21 WO PCT/EP2021/087031 patent/WO2022136393A1/fr active Search and Examination
Also Published As
Publication number | Publication date |
---|---|
WO2022136393A1 (fr) | 2022-06-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11524024B2 (en) | Compounds to modulate intestinal absorption of nutrients | |
WO2019236525A1 (fr) | Formulations de produit à base de soie et procédés d'utilisation | |
US20190111107A1 (en) | Methods for modulating intestinal microbiota | |
JP2960947B2 (ja) | 脂質分解酵素阻害剤 | |
US8927032B2 (en) | Methods for treating metabolic disorders | |
JP6668327B2 (ja) | 生理活性で、ナノカプセル化された抗酸化物質の送達 | |
EP4267114A1 (fr) | Nanoparticules de zéine destinées à être utilisées dans des pathologies avec hyperglycémie | |
EP2444078B1 (fr) | Utilisation d'amides d'acides mono- et dicarboxyliques pour le traitement des maladies rénales | |
Roque-Borda et al. | HPMCAS-Coated Alginate Microparticles Loaded with Ctx (Ile21)-Ha as a Promising Antimicrobial Agent against Salmonella Enteritidis in a Chicken Infection Model | |
WO2005074961A1 (fr) | Agent luttant contre les reserves lipidiques de l'organisme | |
KR101755360B1 (ko) | 난각막 성분을 포함한 인슐린 저항성 개선제 및 그것을 이용한 조성물 | |
KR100939983B1 (ko) | 히아루론산-소수성 폴리 아미노산 공중합체 | |
KR101627455B1 (ko) | 항균활성을 가지는 키메라 펩타이드 및 이를 함유하는 항균용 조성물 | |
KR101717352B1 (ko) | 안토시아닌 및 금 나노입자의 결합체를 포함하는, 퇴행성 뇌질환의 예방 및 치료용 조성물 | |
EA039314B1 (ru) | Фармацевтически приемлемые соли полипептидов и их применение | |
Gao et al. | Combating bacterial infections with host defense peptides: Shifting focus from bacteria to host immunity | |
WO2002049636A1 (fr) | Composition antidiabetique a base d'aminoacides | |
KR102265418B1 (ko) | 돼지 막창 추출물을 포함하는 당뇨병 예방 또는 치료용 조성물 | |
AU2014215958B2 (en) | Methods for treating glucose metabolic disorders | |
WO2006085523A1 (fr) | Composition inhibant l’augmentation du niveau de glycemie | |
EP2724723A1 (fr) | Tégasérod pour un usage dans le traitement de lésions nerveuses | |
Mohammad | Novel therapeutic targets for organ injury and dysfunction in systemic inflammation | |
WO2000062796A1 (fr) | Agents de traitement des troubles de la fonction pancreatique | |
CN116139294A (zh) | 一种l-谷氨酰胺-玉米醇溶蛋白-柚皮素纳米颗粒及其应用 | |
JP2021019532A (ja) | 血液脳関門保護剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: UNKNOWN |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20230717 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) |